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 The disruption of neurotrophic support factors, such as brain-derived neurotrophic 
factor (BDNF), has been implicated in the risk of Alzheimer’s disease and related 
disorders (ADRD). The investigation of genetic markers of BDNF has shown an 
association with ADRD risk with sex-dependent effects, though the associations with 
cognitive and behavioral progression after dementia diagnosis is less known. The current 
research examined the relationships between BDNF single-nucleotide polymorphisms 
(SNPs) and cognitive and neuropsychiatric symptom progression after dementia onset in 
the longitudinal, community-based Cache County Study on Memory in Aging and 
subsequent Dementia Progression Study. 
Nine hundred thirty-one participants (61.3% female) were diagnosed with ADRD 
(68.2% Alzheimer’s disease with or without another dementia; 13.5% Vascular 
Dementia; 18.3% Other Dementia) and assessed using the Consortium to Establish a 
Registry for Alzheimer’s Disease neuropsychological battery (CERAD-NP) and 
Neuropsychiatric Inventory (NPI). Participants were identified with dementia in four 
triennial waves and re-examined at intervals ranging from six to 18 months. The 
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following SNPs were examined: rs6265 (BDNF G196A/Val66Met), rs56164415 (BDNF 
C270T), rs2289656 (BDNF receptor TrkB), and rs2072446 (Nerve Growth Factor 
receptor p75NTR). Linear mixed-effects models were used to investigate cognitive and 
neuropsychiatric progression by SNP; Sex x SNP interactions were also examined. 
Relevant covariates included age of dementia onset, level of education, apolipoprotein E 
genotype, dementia duration at baseline, and dementia type. 
Mean age of dementia onset was 82.0 (SD = 7.1) with mean baseline dementia 
duration of 2.9 years (SD = 2.7). All four SNPs demonstrated sex-dependent effects, with 
non-linear effects over time (p < .05) across several cognitive measures from the 
CERAD-NP. Sex-dependent effects were also observed in rs56164415 for NPI Apathy 
scores and in rs2289656 for NPI Anxiety scores. Additionally, rs6265 and rs56164415 
genotype was associated with NPI Agitation/Aggression, as was rs6265 and rs2072446 
regarding NPI Delusions, independent of sex. 
BDNF genotypes were associated with both cognitive progression and 
neuropsychiatric symptom presentation after dementia onset in a sample of community-
based participants, with sex-dependent effects observed. The current results provide 
evidence of neurotrophin signaling disruption in dementia and highlights the need to 
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The Cache County Study on Memory in Aging (CCSMA) and subsequent 
Dementia Progression Study (DPS) were two research studies that took place in Cache 
County, Utah. These studies followed 5092 participants aged 65 or older for 
approximately 12 years and looked at risk and protective factors for dementia, including 
Alzheimer’s disease. One of the factors investigated was genes that are known to 
influence brain health, such as brain-derived neurotrophic factor (BDNF), a protein found 
in the brain that helps with the survival of brain cells. 
BDNF genes have been shown to be associated with Alzheimer’s disease and 
related dementia (ADRD) risk, but little is known about the influence these genes have 
after dementia is diagnosed. The current study looked at how BDNF related genes were 
associated with learning and memory abilities (i.e. cognitive ability) and problematic 
behaviors (e.g. delusions, agitation/aggression, anxiety) in individuals from the CCSMA 
and DPS who were diagnosed with ADRD. This research is important to help understand 
what may contribute to often-seen differences in dementia progression and help inform 
possible treatment decisions. 
The results of the current project showed that BDNF genes influenced both 
progression of cognitive difficulties and problematic behaviors in individuals with 
ADRD. Additionally, it was shown that many of these effects depended on the sex of the 
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individual, such that men and women progressed at different rates and were influenced by 
different BDNF related genotypes. These results provide evidence of the influence of 
BDNF genes after dementia diagnosis and highlights the need to investigate contributing 
factors related to the sex of the individual. Targeted medication or behavioral treatment 
of dementia that both improves BDNF function in the brain, as well as mitigates any sex-
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 Alzheimer’s disease and related disorders (ADRD) are a global health concern, 
with 5.8 million adults over the age of 65 who have Alzheimer’s disease (AD) in the 
United States alone (Hebert et al., 2013). While AD is the most common form of 
neurodegenerative dementia at an estimated 60 to 80% of all cases, approximately 50% 
of AD cases also include mixed-pathology, such as the presence of vascular dementia 
(Brenowitz et al., 2017). One of the prevailing theories regarding the etiology of AD 
includes the formulation of intercellular beta-amyloid plaques and intracellular 
neurofibrillary tau tangles in the brain, the accumulation of which leads to cell death. The 
excess accumulation and deposition of other proteins have also been seen in other 
neurodegenerative dementias [e.g. excess alpha-synuclein in Lewy body dementia 
(LBD)] suggesting possible shared dysfunction of intra- and intercellular neuronal 
processes (Benussi et al., 2017). Research has also implicated the disruption of 
neurotrophic support factors, such as brain-derived neurotrophic factor (BDNF), in the 
etiology of ADRD (Benussi et al., 2017). Neurotrophic factors support neuronal growth, 
survival, and differentiation of neurons and are synthesized in the central and peripheral 
nervous systems (Huang & Reichardt, 2001). A review of preliminary research regarding 
the role of BDNF in ADRD suggests that reduced BDNF production may increase beta-
amyloid and that both increased alpha-synuclein and tauopathies disrupt BDNF 
trafficking and expression (Benussi et al., 2017). Therefore, the role of BDNF in ADRD 
warrants further investigation.  
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Genetic markers, such as single-nucleotide polymorphisms (SNPs), have been 
investigated in neurotrophic factor genes and have been implicated in dementia. SNPs are 
often examined in genetic models due to their relatively high frequency in populations, 
making them potential biomarkers. One SNP that has garnered significant research is 
Val66Met (rs6265) on the BDNF gene. Val66Met is considered a functional SNP as it 
produces a valine to methionine amino acid substitution on codon 66 of the BDNF gene 
and results in differential expression of BDNF in the hippocampus (Egan et al., 2003). 
While research has shown that the minor Met allele of the SNP Val66Met is associated 
with AD risk (Fukumoto et al., 2010; Lin et al., 2014), other research has found no such 
association (Kim et al., 2012). However, sex-dependent effects of Val66Met (Fukumoto 
et al., 2010; Lin et al., 2014) and other BDNF SNPs (Matyi et al, 2017) regarding risk for 
AD have emerged, suggesting underlying biological differences between men and 
women regarding the role of BDNF and AD risk. Although previous research has shown 
associations between BDNF SNPs and ADRD risk, few studies have explored the 
association of these SNPs with factors related to ADRD progression, namely the 
progression of cognitive impairment and occurrence of neuropsychiatric symptoms 
(NPS) after the onset of dementia.  
While the initial cognitive presentation of AD varies, early complaints of 
decreased ability to remember names, events, or conversations are common (Cummings, 
2000). In mid-stage, there may be worsening ability to learn new information and recall 
memories, with impairments in visuospatial ability, abstract reasoning, and word-list 
generation (Cummings, 2000). Finally, in the end stages of the disease, most cognitive 
functions are severely impaired, ultimately leading to organ failure and eventually death 
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(Cummings, 2000). While this is an informative example of cognitive trajectory for AD, 
the cognitive progression of ADRD is often non-linear and varies by the severity of 
cognitive impairment (Cummings, 2000; Morris et al., 1993; Stern et al., 1994) and 
dementia type. For instance, when compared to AD, fronto-temporal dementia (FTD) is 
characterized by earlier onset and more rapid cognitive decline (Rascovsky et al., 2005), 
while vascular dementia (VaD) is associated with a slower decrease in cognitive ability. 
Even within AD, the annual rate of cognitive change measured by the Mini-Mental Status 
Examination (MMSE) has been shown to vary significantly between 0.8 – 4.4 points-per 
year (Behl et al., 2005), suggesting the influence of many factors including age (Tschanz 
et al., 2011; Wilson et al., 2000) and sex (Tschanz et al., 2011), as well as vascular risk 
factors (Mielke et al., 2007) and modifiable risk factors such as physical activity and 
cognitive stimulation (Hersi et al., 2017).  
Neurotrophic factor genes have also been investigated in the cognitive 
progression of ADRD, with mixed results. Some studies have shown an association of 
BDNF SNPs with cognitive decline in mild cognitive impairment (MCI) and not AD 
(Forlenza et al., 2010; Honea et al., 2013), while others have shown the association in the 
presence of high beta-amyloid accumulation in preclinical AD (Boots et al., 2017; Lim et 
al., 2013). Others have found no association with BDNF SNPs and cognitive decline in 
AD (Chuu et al., 2006; Zdanys et al., 2009). Some of the limitations to previous studies 
include use of hospital/clinic convenience samples, small sample sizes, restricted 
statistical modeling of inheritance patterns, and limited cognitive measurement. 
Additionally, sex differences have only been examined in one study (Honea et al., 2013), 
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with no interaction found between Val66Met and sex in cognitive or neuroimaging 
measures. 
 Along with cognitive changes, NPS are also a common feature of ADRD 
(Steinberg et al., 2008). Defined broadly, NPS are behavioral and mood disturbances that 
are associated with a neurological syndrome or disease (Cummings 1994). Typically, the 
occurrence or severity of NPS increase over the course of dementia, though at different 
rates of frequency and severity (Steinberg et al., 2008; Tschanz et al., 2011; Wetzels et 
al., 2010). In the early course of AD, the most common NPS include apathy, depression, 
and anxiety, while later stages may be associated with increased agitation, aggression, 
and delusions (Lyketsos et al., 2011). In the final stages of dementia, NPS are very 
common and increase in severity with increased cognitive impairment (Rozum et al., 
2019). NPS have also been associated with progression from mild cognitive impairment 
(MCI) to dementia (Peters et al., 2013) and from mild to severe dementia (Peters et al., 
2015). 
Neurotrophic factors have also been implicated in NPS, possibly due to shared 
mechanisms underlying psychiatric symptoms (e.g. depression) and dementia (Wenzler et 
al., 2017; Ye et al., 2016; Zanardini et al., 2016). However, the investigation of genetic 
associations between BDNF and NPS in ADRD have been limited. BDNF SNPs have 
been associated with AD-related depression in an Italian (Borroni et al., 2009) and 
Chinese sample (Zhang et al., 2011), while a Brazilian study showed an association with 
BDNF SNPs and depression and anxiety in Parkinson’s disease (Cagni et al., 2017). In a 
US sample of largely European-American (~97%) individuals with AD, the BDNF SNP 
C270T was shown to be associated only with the presence of hallucinations (Zdanys et 
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al., 2009). Another study examined potential sex differences of NPS in AD in a 
Caucasian-Croatian sample and found that the minor allele of Val66Met was associated 
with increased psychotic symptoms (i.e. delusions and hallucinations) in men, but not 
women (Pivac et al., 2011). As with studies looking at cognitive progression in ADRD, 
the current literature regarding BDNF SNPs and NPS in ADRD has several limitations, 
including reliance of hospital/clinic convenience samples, small sample sizes, restricted 
statistical modeling of inheritance patterns, and limited investigation of potential sex 
differences. To the best of our knowledge, the associations between neurotrophic factor 
genetics and NPS in ADRD have not been examined in a large-scale, longitudinal, 
community-based sample. 
 The current research utilized extant data from the Cache County Study on 
Memory in Aging (CCSMA; see Breitner et al., 1999) and subsequent Dementia 
Progression Study (DPS; see Tschanz et al., 2011). The original CCSMA consisted of a 
population-based longitudinal cohort study involving 90% of the residents of Cache 
County, Utah aged 65 or older (Breitner et al., 1999). Participants were followed across 
four triennial waves for approximately 12 years. Follow-up visits for individuals who 
were diagnosed with dementia at baseline (prevalent cases), as well as those diagnosed 
over the course of the study (incident cases) are available for cognitive, functional, and 
neuropsychiatric outcomes after the onset of dementia. The aims of the current project are 
two-fold: 1) to determine whether several BDNF SNPs are associated with differential 
cognitive progression in a group of individuals diagnosed with ADRD and 2) to 
determine NPS presentation over time by those BDNF SNPs. Furthermore, potential sex 












 Alzheimer’s disease and related disorders (ADRD) are a current public health 
concern in the United States, with AD being the fifth leading cause of death in 
individuals 65 and older (Alzheimer's Association, 2018). Additionally, ADRD are 
associated with significant financial and caregiving costs (Dwibedi et al., 2018). While 
“memory complaints” are common in AD, cognitive changes in other domains (e.g. 
language; executive functioning; visuospatial processing) are heterogeneous in ADRD 
with differential rates of decline (Bruandet et al., 2009; Morris et al., 1993; Rascovsky et 
al., 2005; Stern et al., 1994). Furthermore, the neuropathological mechanisms of ADRD 
are not fully understood and include several models, such as the formation of amyloid-β 
(Aβ) plaques and neurofibrillary tangles of tau protein that inhibit cellular function and 
promote apoptosis, as well as the disruption of neurotrophic support mechanisms 
(Benussi et al., 2017). 
 
Cognitive Progression in ADRD 
 
 The rate of cognitive progression in ADRD is non-linear and can vary by the 
severity of cognitive impairment (Morris et al., 1993; Stern et al., 1994) and dementia 
type. Compared to AD, fronto-temporal dementia (FTD) is associated with more rapid 
cognitive decline (Rascovsky et al., 2005), while vascular dementia (VaD) has slower 
cognitive decline (Bruandet et al., 2009). Variability of the annual rate of change (ARC) 
7 
 
in AD measured by the Mini-Mental Status Examination (MMSE) has been demonstrated 
to be between 0.8 – 4.4 points-per year (Behl et al., 2005), suggesting the influence of 
many factors. Regarding demographics, baseline age has been shown to predict the rate 
of cognitive decline in AD (Wilson et al., 2000), as well as age of disease onset (Tschanz 
et al., 2011; Wilson et al., 2000), such that younger individuals decline more rapidly 
compared to older individuals. In a longitudinal comparison including incident AD cases, 
women demonstrated faster decline compared to men (Tschanz et al., 2011). Genetic 
inheritance of the E4 allele of the apolipoprotein E (APOE) gene has demonstrated risk 
for sporadic AD (Breitner et al., 1999) and VaD (Chuang et al., 2010) onset, but has not 
been consistently associated with cognitive decline after dementia onset (Hersi et al., 
2017; Tschanz et al., 2011). While some consistencies in demographic variables (e.g., age 
of onset; sex) appear in rates of cognitive decline in AD, significant individual variability 
remains. Modifiable risk factors are also associated with rate of cognitive decline in AD. 
In a systematic review of risk factors associated with AD progression (Hersi et al., 2017), 
only physical activity and cognitive stimulation demonstrated significant "protective" 
effects; no effects were reported for educational attainment or dietary factors. A history 
of vascular risk factors and their treatments has also been shown to predict rates of 
cognitive progression in AD (Mielke et al., 2007).  
 
Neurotrophin Genetics in ADRD 
 
 Genes involved in neurotrophin signaling, such as brain-derived neurotrophic 
factor (BDNF), have been investigated in ADRD. Broadly, the neurotrophins are a class 
of trophic factors that promote synaptic growth,  survival and differentiation of neurons 
[see Dawbarn and Allen (2003) and Huang and Reichardt (2001) for a full review of 
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neurotrophins and their signaling pathways]. Specifically, disrupted BDNF production 
and signaling has been shown in ADRD (Dawbarn & Allen, 2003). BDNF protein and 
mRNA expression is reduced in the hippocampus in AD [see Benussi et al. (2017) for 
review], and BDNF in serum is reduced in AD, FTD, Lewy-body dementia (LBD), and 
VaD compared to healthy controls (Ventriglia et al., 2013). Additionally, in several 
mouse models of AD, treatment with BDNF has demonstrated reductions in AD-related 
phenotypes, such as learning and memory impairment and Aβ deposition (Benussi et al., 
2017). 
Single-nucleotide polymorphisms (SNPs) have been identified on the BDNF gene 
and are related to neuronal mechanisms involved in ADRD. Val66Met (rs6265), 
considered a functional SNP due to an amino acid substitution of valine to methionine at 
codon 66 of the BDNF gene, has been shown to affect activity-dependent production of 
BDNF in the hippocampus (Egan et al., 2003). Increased risk for AD has been reported in 
BDNF SNPs such as Val66Met (Fukumoto et al., 2010; Lin et al., 2014), C270T (Ji et al., 
2015; Nishimura et al., 2005; Olin et al., 2005), and rs2072446 and rs56164415 (Matyi et 
al., 2017). However, associations with AD risk have been shown to differ by sex and 
ethnicity. Meta-analyses have reported an increased risk for AD in only female minor 
allele-carriers of Val66Met (Fukumoto et al., 2010; Lin et al., 2014; Zhao et al., 2018), 
though in one analysis this became non-significant when controlling for age and APOE 
status (Zhao et al., 2018). In a meta-analysis comparing European to Asian populations 
(Ji et al., 2015), the authors found an association between minor allele-carriers of BDNF 
SNP C270T and AD risk in Asian populations only. Several limitations currently remain 
in the research on BDNF SNPs and ADRD risk, including limited investigation of 
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stratification effects (e.g. sex) and inheritance models (i.e. dominant vs codominant), and 
the inconsistent inclusion of relevant covariates of ADRD risk (e.g. age; APOE status). 
 
BDNF SNPs and Cognitive Decline in ADRD 
 
While there is some evidence that the minor alleles of certain BDNF SNPs show 
increased risk for ADRD, the association between BDNF SNPs and cognitive decline 
after the onset of dementia is less clear. Several studies have shown an association of 
Val66Met and  cognitive decline in preclinical stages of AD in the presence of high Aβ 
accumulation (Boots et al., 2017; Lim et al., 2013) suggesting an interaction between 
dysfunctional neurotrophic signaling and Aβ accumulation. Forlenza et al. (2010) 
however, reported that carriers of the minor allele of Val66Met showed steeper cognitive 
decline in individuals with mild cognitive impairment (MCI), but not AD in a Brazilian 
sample. Additionally, the article demonstrated a gene by gene interaction such that minor 
allele carriers of Val66Met and E4 of APOE showed the most rapid decline in MCI 
participants. Honea et al. (2013) found similar results from the Alzheimer’s Disease 
Neuroimaging Initiative (ADNI) database in that three BDNF SNPs (rs1157659, 
rs11030094, rs11030108) were associated with cognitive decline (1 and 2-year follow-
up) in non-demented controls (N = 175) and MCI participants (N = 316), but not in AD 
(N = 154). However, two BDNF SNPs (rs908867, rs1491850) were associated with 
increased hippocampal atrophy over 2 years in AD, but not MCI. In another study using a 
convenience sample of 341 patients diagnosed with probable AD, Zdanys et al. (2009) 
found no association between BDNF polymorphisms Val66Met and C270T and rate of 
cognitive decline measured via the MMSE and the Alzheimer’s Disease Assessment 
Scale, cognitive subscale (ADAS-Cog). Chuu et al. (2006) also found no association 
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between Val66Met and cognitive decline (via MMSE) in a sample of 149 individuals 
with AD. However, the authors discussed a trend that Met homozygotes appeared to have 
faster rates of decline, though this did not reach statistical significance and was limited by 
a small sample size (n=5). Several limitations exist to the current literature. First, all 
articles discussed employed clinical sampling of AD cases, possibly limiting the 
generalizability of the results. To the best of our knowledge, the association between 
cognitive decline in AD and BDNF SNPs has not been investigated in a population-based 
sample. Several of the studies also reported small sample sizes of AD cases, with limited 
follow-up, potentially limiting power to detect smaller effects and to detect changes over 
the variable course of ADRD. Small sample size may also contribute to reliance on 
restricted statistical analyses (e.g. dominant model only; A/A vs A/a and a/a), which is 
limiting as research has not shown a clear inheritance pattern for BDNF SNPs. 
Furthermore, while the MMSE may capture a global measure of cognition, it does little to 
show domain-specific changes that can be observed in dementia (Alzheimer's 
Association, 2018). Lastly, only one of the papers examined sex-dependent effects of 
BDNF SNPs in AD (Honea et al., 2013) with no interaction found. However further 
exploration of sex-dependent effects is warranted in a larger, population-based sample. 
The current research used extant data from 931 individuals with ADRD from a 
large population-based study of risk factors of dementia and its progression, to examine 
the association between several BDNF related SNPs and cognitive decline after the onset 












The current research used extant data from 931 individuals identified with 
dementia from the Cache County Study on Memory in Aging [CCSMA; see Breitner et 
al. (1999)], and followed in the Cache County Dementia Progression Study [DPS; see 
Tschanz et al. (2011)]. The county-wide ascertainment of dementia in those aged 65 
years or older in 1995, occurred in 4 triennial waves that occurred in 1995, 1998, 2002, 
and 2005 (Breitner et al., 1999; Miech et al., 2002). Demographic and genetic variables 
were ascertained, including age, level of education, and APOE genotype. The majority 
(99%) of participants were Caucasian. All procedures were approved by the Institutional 







A multi-staged dementia screening and assessment protocol was performed at all 
four waves of the CCSMA. Cognitive screening was conducted using an adaptation 
(Tschanz et al., 2002) of the 100-point modified Mini-Mental State Examination (3MS) 
(Teng & Chui, 1987) or if unable, dementia screening with a proxy using the Informant 
Questionnaire for Cognitive decline (IQCODE) (Jorm & Jacomb, 1989). In Waves 1 and 
2, participants who scored < 87 on the 3MS or whose IQCode was above 3.27 were sent 
to the Dementia Questionnaire (DQ) stage, consisting of an interview with a 
knowledgeable informant regarding identification of dementia symptomology. 
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Participants identified as having significant cognitive impairment (rated by a 
neuropsychologist or geropsychiatrist) or who were members of a randomly selected 
panel to complete all stages of screening and assessment, were selected to complete a 
clinical assessment. The clinical assessment included neuropsychological testing, medical 
and neurological evaluation, and clinical interview with a knowledgeable informant. 
Results of the assessment were reviewed and preliminary diagnoses of a cognitive 
condition (if any) were assigned. Diagnoses of dementia followed Diagnostic and 
Statistical Manual (DSM-III-R) criteria (APA, 1987). The expert panel reviewed all 
clinical data, diagnosed dementia, and assigned age of onset based on a chronology of 
symptoms when the individual met DSM-III-R criteria. Differential diagnosis of AD and 
vascular dementia (VaD) followed criteria specified by the National Institute of 
Neurological and Communicative Disorders and Stroke and the Alzheimer’s Disease and 
Related Disorders Association (NINCDS-ADRDA; McKhann et al., 1984) and National 
Institute of Neurological Disorders and Stroke and Association Internationale pour la 
Recherché et l’Enseignement en Neurosciences (NINDS-AIREN; Román et al., 1993), 
respectively. Persons who were not identified with dementia at a given wave were 
followed at the subsequent wave(s) using similar procedures, except for the elimination 
of the DQ stage in Waves 3 and 4 and completion of a clinical assessment for those aged 
90 and above. Those with AD or other forms of dementia received an 18-month clinical 
assessment to assess progression of dementia. 
 
Dementia Progression Study 
 
In 2002, surviving individuals diagnosed with dementia in CCSMA were invited 
to enroll in a follow-up study of dementia progression (Tschanz et al., 2011). 
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Additionally, individuals with newly diagnosed incident dementia in the CCSMA (Waves 
2 – 4) were invited to participate in the DPS. The follow-up visits were similar to those of 




 Cognition was assessed using both global [e.g. MMSE; (Folstein et al., 1975)] and 
more specific measures of cognitive function. The 1-hour Consortium to Establish a 
Registry for Alzheimer’s Disease Neuropsychological Battery [CERAD-NB; (Morris et 
al., 1989; Welsh et al., 1994)] captures performance of immediate memory and delayed 
memory [Word List: immediate (range 0 – 30), delayed (range 0 – 10), and recognition 
trials (range 0 – 20); Constructional Praxis: delayed and recognition trials (range 0 - 11)], 
language/executive functioning [Boston Naming (range 0 – 30; prorated from 15-item at 
CCSMA Wave 1) and Animal Fluency], and visuospatial ability (Constructional Praxis 
Copy; range 0 – 11). The CERAD-NB is a well-validated measure of cognitive ability in 
dementia and has good test-retest (r = .80 - .91) and interrater (r = .92 - 1.0) reliability 
(Fillenbaum et al., 2008). The current study employed sensory-adjusted scores for the 
MMSE to account for vision and hearing corrections, as well as a pro-rated Boston 




APOE genotyping was completed on buccal DNA as described previously 
(Breitner et al., 1999). BDNF genotyping was subsequently performed for four BDNF-
related SNPs [rs6265 (Val66Met; G196A), rs56164415 (C270T), rs2289656 (receptor 
TrkB), and rs2072446 (receptor p75NTR)] using standard TaqMan® Assays (Life 
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Technologies). Due to the unknown model of inheritance of these SNPs, codominant 
(A/A vs. A/a vs. a/a) models were assessed as sample sizes allowed, otherwise followed 
by dominant (A/A vs A/a and a/a) models. Hardy-Weinberg Equilibrium (HWE) testing 
was previously performed on the total CCSMA sample (Matyi et al., 2017) and showed 




 Factors associated with BDNF genetics and cognitive progression in ADRD were 
examined in statistical models. These included age of dementia onset, level of education, 
APOE genotype (no E4 alleles vs. 1 or more E4 allele), and dementia duration to baseline 
(Laske et al., 2006). Furthermore, as neurotrophic mechanisms have implications in all 
neurodegenerative disease, dementia type (AD with or without other dementia; VaD; 




Descriptive statistics were performed for the sample, including comparisons for 
participants included vs. excluded in the analyses using Chi-square tests for categorical 
variables and independent samples t-tests for continuous variables. A series of linear 
mixed-effects models was employed to investigate the association of BDNF SNP 
inheritance on cognitive decline in ADRD. In addition to examining fixed effects, mixed 
effects models address within-subject correlation and random effects inherent in 
longitudinal data (Oberg & Mahoney, 2007). Furthermore, these models allow for 
missing data across time points and do not exclude cases on a list-wise basis. As 
cognitive progression was hypothesized to include different starting points and 
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trajectories for each participant, both random intercepts and slopes were employed to 
account for this variance. 
Statistical models were constructed as follows: trajectory was assessed for each 
dependent cognitive test variable comparing intercept only, time, and quadratic time (i.e. 
time2). Thereafter, main effect models included all covariates of interest, run separately 
for each SNP. Covariates were retained regardless of statistical significance due to 
previous empirical support on their effects of cognitive progression in dementia. 
Interaction terms were subsequently included in each model, starting with investigation 
of the association of a SNP on cognitive progression over time (SNP x time and time2). 
Likelihood Ratio Tests (LLRT) were employed to determine improvement in model fit (p 
< .05) of nested models. Additional interactions were then built to include hypothesized 
effects of sex [SNP x time (or time2) x sex] and were compared to lower order models 
using LLRT. When minor allele frequencies allowed, model building started with 
codominant (A/A vs. A/a vs. a/a) comparisons, or otherwise employed dominant (A/A vs. 
A/a and a/a) models. Maximum likelihood estimation (ML) was used during the iterative 
building process, while restricted maximum likelihood estimation (REML) was used on 
final models to obtain parameter estimates for all factors. To account for possible 
multiple comparisons effects, Bonferroni correction was applied to the final models (4 
SNPs x 7 outcomes = 36; p < .0018). All statistical models were run using the lme4 












 Out of 931 eligible participants with dementia, 51 participants were excluded due 
to lack of genotyping data across all four BDNF protein and receptor SNPs, leaving a 
final sample of 880. This sample was composed of 61.3% female participants, had a 
mean age of dementia onset at 82.0 years (SD = 7.1), and a mean education level of 13.0 
years (SD = 3.0). Excluded participants had longer mean duration of dementia pre-
baseline (p = .021) and lower mean level of education (p = .026) compared to included 
participants. Table 1 summarizes descriptive statistics for included vs. excluded 
participants. 
 
Table 1            
            
Study I: Baseline Participant Characteristics Comparing those Included vs Excluded 
in Analyses 
 
Variable Included (n = 880) Excluded (n = 51)    
M SD N % M SD N % t χ2 p 
Onset 
Age 82.0 7.1   82.6 5.7   -0.40  .689 
Dem Dur 
(yrs) 2.9 2.7   3.8 3.1   2.30  .021* 
Education 
(yrs) 13.0 3.0   12.0 2.6   -2.22  .026* 
Sex          0.12 .730 
   Male   341 38.8   18 35.3    
   Female   539 61.3   33 64.7    
APOE E4          0.77 .379 
   No E4   455 51.7   28 54.9    
   1 or 
more E4   422 48.0   19 37.3    
   Missing   3 0.3   4 7.8    
Dementia 
Type          1.23 .541 
   AD a   600 68.2   34 66.7    
   VaD   119 13.5   5 9.8    
   Other   161 18.3   12 23.5    
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Note. Dem Dur = Baseline Dementia Duration 
a AD with or without a second type of dementia 
* p < .05 
 
The final sample was then stratified by sex to identify differences per 
hypothesized sex effects. Compared to males, female participants were older at dementia 
onset (p < .001), had fewer years of education (p < .001), and differed in dementia 
etiology, namely higher frequency of AD and lower frequency VaD (p < .001). 
Additionally, there were no significant differences in genotype frequencies between men 
and women. Baseline cognitive performance was also examined and showed that 
compared to males, female participants had lower scores across all neuropsychological 
measures except MMSE, Word List Immediate Recall, and Constructional Praxis Copy, 
despite non-significant difference in dementia duration. Furthermore, results indicate 
minimal variance at baseline for both Word List Delayed Recall and Constructional 
Praxis Delayed Recall across both men and women. Therefore, both delayed recall 
measures were excluded from model analyses. Table 2 shows the descriptive statistics by 
sex. 
 
Table 2            
            
Study I: Baseline Descriptive Comparisons by Sex 
 
Variable Female (n = 539) Male (n = 341)    
M SD N % M SD N % t χ2 p 
Onset Age 82.7 6.9   80.9 7.3   -3.84  <.001*** 
BL Dem Dur 
 (yrs) 3.1 2.6   2.8 2.8   -1.66  .097 
Follow-up (yrs) 1.9 2.4   1.9 2.3   0.36  .719 
Education (yrs) 12.6 2.6   13.5 3.5   4.00  <.001*** 
APOE E4           0.97 .324 
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   No E4   271 50.3   184 54.0    
   1 or more E4   266 49.4   156 45.7    
   Missing   2 0.4   1 0.3    
Dementia Type          16.89 <.001*** 
   AD a   395 73.3   205 60.1    
   VaD    63 11.7   56 16.4    
   Other   81 15   80 23.5    
Prev/Inc Dem          0.40 .525 
   Prevalent   204 37.8   121 35.5    
   Incident   335 62.2   220 64.5    
SNP            
   rs6265          0.08 .961 
      G/G   344 60.1   222 61.8    
      G/a   167 29.2   105 29.2    
      a/a   22 3.8   13 3.6    
      Missing   39 6.8   19 5.3    
   rs2289656          0.60 .742 
      C/C   341 59.6   213 59.3    
      C/t   159 27.8   100 27.9    
      t/t   21 3.7   17 4.7    
      Missing   51 8.9   29 8.1    
   rs2072446          4.34 .114 
      C/C   475 83   319 88.9    
      C/t   48 8.4   18 5    
      t/t   4 0.7   2 0.6    
      Missing   45 7.9   20 5.6    
   rs56164415          0.06 .811 
      C/C   459 80.2   294 81.9    
      C/t   64 11.2   38 10.6    
      t/t   0 0   0 0    
      Missing   49 8.6   27 7.5    
BL Cog 
 Scores            
   MMSE 18.5 8.1   19.2 7.5    1.09 .276 
   WL Imm 8.7 5.0   8.9 5.1    0.31 .757 
   WL Del 1.3 1.6   1.7 1.7    3.31 <.001*** 
   WL Recog 13.7 6.1   15.0 5.5    2.97 .003** 
   PX Copy 7.5 3.2   8.0 2.9    1.81 .070 
   PX Delay 2.1 2.2   3.0 2.7    4.82 <.001*** 
   PX Recog 2.6 1.2   3.0 0.9    3.30 .001** 
   BNT 16.2 8.3   19.4 7.5    5.10 <.001*** 
   Animal 7.6 4.6   9.6 5.2    5.77 <.001*** 
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Note. BL Dem Dur = Baseline Dementia Duration; BL Cog Scores = Baseline Cognitive 
Scores; Prev/Inc Dem = Prevalent and Incident Dementia Cases; MMSE = Mini-Mental 
State Examination; WL Imm = Word List Immediate Recall; WL Del = Word List 
Delayed Recall; WL Recog = Word List Recognition; PX Copy = Constructional Praxis 
Copy; PX Del = Constructional Praxis Delayed Recall; PX Recog = Constructional 
Praxis Recognition; BNT = Boston Naming; Animal = Animal Fluency 
a AD with or without a second type of dementia 
* p < .05. ** p < .01. *** p < .001 
 
Neuropsychological Outcomes  
Bivariate correlations were calculated across all cognitive outcome variables at 
baseline. All tests showed positive medium to large correlation coefficients (range = .30 
to .84) with each other, though only MMSE and Word List Recognition (r = .81), MMSE 
and Constructional Praxis Copy (r = .84), and Word List Recognition and Constructional 
Praxis Copy (r = .77) were significant at the p < .05 level. Additionally, MMSE scores 
were more consistently correlated with all other measures, supporting its use as a global 
measure of cognitive abilities. Appendix Supplemental Figure A 1 displays the 
correlation matrix of baseline neuropsychological measures. 
 
Overview of Exploratory Statistical Models by SNP 
 
  All cognitive outcomes across all statistical models for each SNP 
declined/worsened over time. The addition of a non-linear (quadratic) time component to 
models with the linear time terms represented the best model fit (all -2 LLRT p < .001), 
apart from Boston Naming (LLRT range p = .252 - .691). Dementia type demonstrated a 
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consistent main effect such that individuals with VaD had higher cognitive scores 
compared to AD. Note that in this instance, models testing interactions of dementia type 
with sex for each SNP did not achieve convergence, likely due to small sample size. 
Thus, dementia type was retained as a covariate in all statistical models as it broadly 
improved model fit (LLRT p < .001). Results of statistical models testing study 
hypotheses are presented by each SNP. 
 
Rs6265 (Val66Met; G169A) 
 
The association between rs6265 (codominant inheritance pattern), and rate of 
cognitive decline on the MMSE and Constructional Praxis Copy differed between male 
and female participants [ANOVA statistics: F(1523, 2) = 6.83, p = .0011 and F(1216, 2) 
= 6.88, p = .0010, respectively for interaction between sex x rs6265 x time2]. When 
examining effects within sex, male participants differed in rates of decline on both the 
MMSE and Constructional Praxis Copy by rs6265 genotype, while female participants 
did not. Figures 1 and 2 show the associations of rs6265 over time stratified by sex for 
MMSE and Constructional Praxis Copy, respectively. Notably, male participants showed 
a consistent effect across cognitive tests such that compared to major homozygotes 
(G/G), heterozygotes (G/a) exhibited a steeper decline, with minor homozygotes 
demonstrating the most rapid decline (a/a).  
The SNP x sex x time interaction was significant for Boston Naming at a trend 
level (p = .0852). Rs6265 was not associated with the rate of change for Word List 
Immediate Recall, Word List Recognition, Constructional Praxis Recognition, and 





MMSE Score Over Time for Females and Males by rs6265 Genotype  
 
Note. Shaded region is one standard error of the mean. Predicted values drop below scale 























Constructional Praxis Copy Score Over Time for Females and Males by rs6265 
Genotype  
 
Note. Shaded region is one standard error of the mean. Predicted values drop below scale 




Fully Adjusted Interaction Models for rs6265 by Cognitive Outcome 
 
Variable MMSE WL Imm WL Recog PX Copy PX Recog Animal BNT 
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APOE E4               
   No E4 - - - - - - - - - - - - - - 
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   1 or 
















 Type  
   AD a - - - - - - - - - - - - - - 



























   Male - - - - - - - - - - - - - - 














   G/G - - - - - - - - - - - - - - 



























 Sex x 
 Time 
              
   G/G x 
   Male x 
   Time 
- - - - - - - - - - - - - - 
   G/a x 
   Female 
   x Time 
- - - - - - - - - - - - 0.56 
(0.38) 
.1446 
   a/a x 
   Female 
   x Time 




 Sex x 
 Time2 
 
   G/G x 
   Male x 
   Time2 
- - - - - - - - - - - - - - 
   G/a x 
   Female 












(0.07) .9103 - - 
   a/a x 
   Female 












(0.15) .2137 - - 
Note. All models included all covariates, as well as main effects and lower order 
interaction terms for each significant interaction, though only highest order interactions 
are reported for each outcome; BL Dem Dur = Baseline Dementia Duration; MMSE = 
Mini-Mental State Examination; WL Imm = Word List Immediate Recall; WL Recog = 
Word List Recognition; PX Copy = Constructional Praxis Copy; PX Recog = 
Constructional Praxis Recognition; BNT = Boston Naming; Animal = Animal Fluency 
a AD with or without a second type of dementia 
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* p < .05. ** p < .01. *** p < .001 
 
Rs56164415 (C270T) 
Due to the absence of homozygous minor allele carriers in rs56164415, all models 
compared heterozygous carriers (C/t) to homozygous major allele carriers (C/C).  The 
association between rs56164415 and rate of cognitive decline on the MMSE, Word List 
Immediate Recall, and Constructional Praxis Copy differed between male and female 
participants [ANOVA statistics: F(1490, 1) = 21.21, p <.001; F(1556, 1) = 5.68, p = 
.0172; and F(1239, 1) = 7.78, p = .0054; for interactions between sex x rs56164415 x 
time2, respectively). When examining effects within sex, both male and female 
participants differed in rates of decline by rs56164415 genotype and outcome. Figures 3, 
4, and 5 show the associations of rs56164415 over time stratified by sex for MMSE, 
Word List Immediate Recall, and Constructional Praxis Copy, respectively. Male 
heterozygotes (C/t) showed a steeper decline than major homozygotes (C/C), though this 
was limited by reduced follow-up for heterozygotes. In general, female heterozygotes 
showed initial rapid decline compared to major homozygotes, though this effect was 
attenuated over time. This pattern was especially pronounced on Word List Immediate 
Recall, where female heterozygotes appeared to reverse direction after approximately 
five years of follow-up.  
The SNP x sex x time2 interaction was significant for Word List Recognition at a 
trend level (p = .0832). Rs56164415 was not associated with rate of change for 
Constructional Praxis Recognition, Boston Naming, and Animal Fluency. Table 4 shows 





MMSE Score Over Time for Females and Males by rs56164415 Genotype  
 
Note. Shaded region is one standard error of the mean. Predicted values drop below scale 



























Note. Shaded region is one standard error of the mean. Predicted values drop below scale 



















Constructional Praxis Copy Score Over Time for Females and Males by rs56164415 
Genotype  
 
Note. Shaded region is one standard error of the mean. Predicted values drop below scale 
limits due to high frequency of zero scores in later years of follow-up. 
 
Table 4 
               
Fully Adjusted Interaction Models for rs56164415 by Cognitive Outcome 
               



















































(0.02) <.001*** - - 
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   No E4 - - - - - - - - - - - - - - 
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   1 or more 
















 Type               
   AD a - - - - - - - - - - - - - - 



























   Male - - - - - - - - - - - - - - 














   C/C - - - - - - - - - - - - - - 














 x Sex x 
 Time 
              
   C/C x 
   Male x 
   Time 
- - - - - - - - - - - - - - 
   C/t x 
   Female x 
   Time 
- - - - - - - - - - - - -0.05 (0.53) .9281 
Rs56164415 
 x Sex x 
 Time2 
 
   C/C x 
   Male x 
   Time2 
- - - - - - - - - - - - - - 
   C/t x 
   Female x 












(0.11) .1486 - - 
Note. All models included all covariates, as well as main effects and lower order 
interaction terms for each significant interaction, though only highest order interactions 
are reported for each outcome; BL Dem Dur = Baseline Dementia Duration; MMSE = 
Mini-Mental State Examination; WL Imm = Word List Immediate Recall; WL Recog = 
Word List Recognition; PX Copy = Constructional Praxis Copy; PX Recog = 
Constructional Praxis Recognition; BNT = Boston Naming; Animal = Animal Fluency 
a AD with or without a second type of dementia 






Rs2289656 (Receptor TrkB) 
The association between rs2289656 (codominant inheritance pattern) and rate of 
cognitive decline on the Word List Immediate Recall, Word List Recognition, 
Constructional Praxis Copy, and Animal Fluency differed between male and female 
participants (ANOVA statistics: F(1407, 2) = 5.03, p = .0067; F(1435, 2) = 4.76, p = 
.0087; F(1119, 2) = 4.87, p = .0078; and F(1472, 2) = 6.14, p = .0022; for interactions 
between sex x rs2289656 x time2, respectively). When examining effects within sex, 
male and female participants differed in rates of decline by rs2289656 genotype. Figures 
6, 7, 8, and 9 show the association of rs2289656 over time stratified by sex for Word List 
Immediate Recall, Word List Recognition, Constructional Praxis Copy, and Animal 
Fluency, respectively. Notably, male heterozygotes (C/t) had slower decline compared to 
major homozygotes (C/C); minor homozygotes (t/t) appeared to have the slowest decline, 
though this did not reach statistical significance across cognitive outcomes. Female 
participants demonstrated the opposite effect, such that compared to major homozygotes 
(C/C), heterozygotes (C/t) had more rapid decline, with minor homozygotes 
demonstrating the most rapid decline (t/t). 
Rs2289656 was not associated with the rate of change for MMSE, Constructional 













Word List Immediate Recall Score Over Time for Females and Males by rs2289656 
Genotype  
 
Note. Shaded region is one standard error of the mean. Predicted values drop below scale 





















Word List Recognition Score Over Time for Females and Males by rs2289656 Genotype 
 
Note. Shaded region is one standard error of the mean. Predicted values drop below scale 























Constructional Praxis Copy Score Over Time for Females and Males by rs2289656 
Genotype  
 
Note. Shaded region is one standard error of the mean. Predicted values drop below scale 













Animal Fluency Score Over Time for Females and Males by rs2289656 Genotype  
 
Note. Shaded region is one standard error of the mean. Predicted values drop below scale 
limits due to high frequency of zero scores in later years of follow-up. 
 
Table 5 
               
Fully Adjusted Interaction Models for rs2289656 by Cognitive Outcome 
               



















































(0.02) <.001*** - - 








































APOE E4               
   No E4 - - - - - - - - - - - - - - 
   1 or more 



















   AD a - - - - - - - - - - - - - - 



























   Male - - - - - - - - - - - - - - 














   C/C - - - - - - - - - - - - - - 



























 x Sex x 
 Time 
              
   C/C x 
   Male x 
   Time 
- - - - - - - - - - - - - - 
   C/t x 
   Female x 
   Time 
- - - - - - - - - - - - 0.10 (0.40) .7984 
   t/t x 
   Female x 
   Time 
- - - - - - - - - - - - -0.24 (1.13) .8280 
Rs2289656 
 x Sex x 
 Time2 
 
   C/C x 
   Male x 
   Time2 
- - - - - - - - - - - - - - 
   C/t x 
   Female x 












(0.05) <.001*** - - 
   t/t x 
   Female x 












(0.30) .1993 - - 
Note. All models included all covariates, as well as main effects and lower order 
interaction terms for each significant interaction, though only highest order interactions 
are reported for each outcome; BL Dem Dur = Baseline Dementia Duration; MMSE = 
Mini-Mental State Examination; WL Imm = Word List Immediate Recall; WL Recog = 
Word List Recognition; PX Copy = Constructional Praxis Copy; PX Recog = 
Constructional Praxis Recognition; BNT = Boston Naming; Animal = Animal Fluency 
a AD with or without a second type of dementia 
* p < .05. ** p < .01. *** p < .001. 
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Rs2072446 (Receptor p75NTR)   
Due to the infrequency of minor homozygotes, only a dominant pattern of 
inheritance (C/C vs C/t and t/t) was examined. The association between rs2072446 and 
rate of cognitive decline on the MMSE and Animal Fluency differed between male and 
female participants (ANOVA statistics: F(1474, 1) = 5.93, p = .0150 and F(1627, 1) = 
5.84, p = .0158, respectively for interactions between sex x rs2072446 x time2). When 
examining effects within sex, female participants differed in rates of decline by 
rs2072446 genotype and outcome, but male participants did not. Figures 10 and 11 show 
the interaction of rs2072446 over time stratified by sex for MMSE and Animal Fluency, 
respectively. Notably, female minor allele carriers (C/t and t/t) showed a slower decline 
than major homozygotes (C/C). 
The SNP x sex x time2 interaction was significant at trend-level for Word List 
Recognition (p = .0869) and Constructional Praxis Recognition (p = .0870). Rs2072446 
was not associated with rate of change for Word List Immediate Recall, Constructional 













MMSE Score Over Time for Females and Males by rs2072446 Genotype  
 
Note. Shaded region is one standard error of the mean. Predicted values drop below scale 














Animal Fluency Score Over Time for Females and Males by rs2072446 Genotype  
 
Note. Shaded region is one standard error of the mean. Predicted values drop below scale 
limits due to high frequency of zero scores in later years of follow-up. 
 
Table 6               
               
Fully Adjusted Interaction Models for rs2072446 by Cognitive Outcome 
               



















































(0.01) <.001*** - - 










































APOE E4               
   No E4 - - - - - - - - - - - - - - 
   1 or more 



















   AD a - - - - - - - - - - - - - - 



























   Male - - - - - - - - - - - - - - 














   C/C - - - - - - - - - - - - - - 














 x Sex x 
 Time 
              
   C/C x 
   Male x 
   Time 
- - - - - - - - - - - - - - 
   C/t & t/t x 
   Female x 
   Time 
- - - - - - - - - - - - -0.58 (0.73) .4293 
Rs2072446 
 x Sex x 
 Time2 
 
   C/C x 
   Male x 
   Time2 
- - - - - - - - - - - - - - 
   C/t & t/t x 
   Female x 












(0.17) .0158* - - 
Note. All models included all covariates, as well as main effects and lower order 
interaction terms for each significant interaction, though only highest order interactions 
are reported for each outcome; BL Dem Dur = Baseline Dementia Duration; MMSE = 
Mini-Mental State Examination; WL Imm = Word List Immediate Recall; WL Recog = 
Word List Recognition; PX Copy = Constructional Praxis Copy; PX Recog = 
Constructional Praxis Recognition; BNT = Boston Naming; Animal = Animal Fluency 
a AD with or without a second type of dementia 
* p < .05. ** p <.01. *** p < .001. 
  
Summary of Results for all SNPs  
Table 7 shows the summary of the SNP x sex x time2 interactions across all SNPs 
and cognitive outcomes. Of note, MMSE was significant after Bonferroni correction for 
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multiple comparisons for rs6265 and rs56164415, as was Constructional Praxis Copy for 
rs6265. 
  
Table 7         
         
SNP x Sex x Time2 Interaction across Cognitive Outcomes 
         
Variable rs6265 rs56164415 rs2289656 rs2072446 
 F p F P F p F p 
MMSE 6.83 .0011† 21.21 <.001† 2.19 .1121 5.93 .0150* 
WL Imm 3.80 .0514 5.68 .0172* 5.03 .0067** 0.88 .3481 
WL 
Recog 
1.90 .1495 2.54 .1108 4.76 .0087** 2.93 .0869 
PX Cop 6.88 .0010† 7.78 .0054** 4.87 .0078** 0.35 .5516 
PX Recog 0.48 .6166 3.01 .0832 0.14 .8674 2.94 .0870 
Animal 0.77 .4613 2.09 .1486 6.14 .0022** 5.84 .0158* 
BNT a 2.49 .0852 0.01 .9281 0.06 .9375 0.63 .4293 
Note. MMSE = Mini-Mental State Examination; WL Imm = Word List Immediate 
Recall; WL Recog = Word List Recognition; PX Copy = Constructional Praxis Copy; 
PX Recog = Constructional Praxis Recognition; BNT = Boston Naming; Animal = 
Animal Fluency 
a Boston Naming interactions did not include quadratic time 





 In the current sample of 880 participants with ADRD from a longitudinal, 
population-based study, sex-dependent effects were observed across four BDNF SNPs in 
the rate of cognitive decline over the course of dementia. Differences were found 
between sexes and within each sex by BDNF SNP. These results add to the growing body 
of literature investigating sex-dependent factors within ADRD and the role of genes 
coding for BDNF or its receptors. 
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 The current study demonstrated differential rates of cognitive decline across male 
and female participants. Compared to male participants, females generally demonstrated 
steeper decline after controlling for relevant covariates, specifically dementia type, age of 
onset, baseline dementia duration, APOE E4 status, and level of education. This is 
consistent with previous research that has shown that females are disproportionately 
affected by cardiometabolic factors in risk for dementia (e.g. diabetes, hypertension, 
hyperlipidemia) that likely contribute to more rapid cognitive decline after diagnosis 
(Mielke et al., 2007; Podcasy & Epperson, 2016). Male and female participants also 
differed in cognitive progression within BDNF SNPs. With regards to the functional 
BDNF protein SNP rs6265 (Val66Met), the current study demonstrated a clear pattern 
across all significant cognitive measures in males, such that for each inherited minor 
allele, a steeper trajectory was observed. In contrast, females did not differ in rate of 
decline by rs6265 genotype. A similar direction of decline was generally observed in 
males for rs56164415 (C270T), also located on the BDNF protein gene, such that minor 
allele carriers showed a steeper decline compared to major homozygotes. Female minor 
allele carriers of rs56164415 also demonstrated a sharper initial decline (~ first 5 years) 
compared to major homozygotes, though this effect was attenuated over time and 
appeared to reverse direction on word list learning performance. One possible cause of 
these attenuated effects are the reduced numbers of female minor allele carriers over 
time, thereby increasing variance over the duration of the study. For the high-affinity 
BDNF receptor TrkB SNP rs2289656, male minor allele carriers showed slower decline 
compared to major homozygotes. Female participants demonstrated the opposite pattern, 
such that such that for each inherited minor allele, a steeper trajectory was observed. 
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Finally, in the low-affinity BDNF receptor p75NTR SNP rs2072446, female minor allele 
carriers showed a slower rate of decline than major homozygotes, while males did not 
differ by genotype.  
Previous research has reported BDNF SNP rs6265 (Val66Met) influences the rate 
of cognitive decline in preclinical AD (Boots et al., 2017; Lim et al., 2013) and MCI 
(Forlenza et al., 2010). Other research has found that rs6265 does not influence the rate of 
progression in MCI (Honea et al., 2013) or AD (Chuu et al., 2006; Honea et al., 2013; 
Zdanys et al., 2009). Honea et al. (2013) also found that three other BDNF SNPs 
(rs1157659, rs11030094, and rs11030108) were associated with cognitive decline in 
healthy controls and MCI, but not AD. These authors suggest that beta amyloid interacts 
with BDNF to play a significant role in AD conversion, though the effect attenuates once 
progression has reached clinical diagnosis, possibly highlighting the influence of other 
neurobiological processes. Only one of the aforementioned studies investigated sex-
dependent effects (Honea et al., 2013) with no effect of sex found. Their sample included 
154 Caucasian individuals with AD who had both higher levels of education [M (SD) = 
14.9 (2.9)] and higher baseline MMSE scores [M(SD) = 23.5 (2.0)], as well as shorter 
follow-up duration (2 years maximum), compared to the current study. To the best of our 
knowledge, only one other study has investigated sex-dependent effects of BDNF SNPs 
in ADRD. In a sample of 213 Han Chinese individuals with MCI or AD, female minor 
allele carriers of rs6265 had more rapid decline at 3-year follow-up relative to major 
homozygotes and males (Li et al., 2017). These results directly contrast with the current 
research, which show male minor allele carriers of rs6265 have the greatest decline 
compared to major homozygotes and females. However, results from Li et al. (2017) 
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were limited to 23 female minor allele carrier cases (1 minor allele homozygote) and had 
shorter follow-up duration compared to the current study. Nevertheless, these results may 
also highlight potential differences across race that previous research has found regarding 
BDNF genetics and AD risk (Ji et al., 2015). 
The sex-dependent results of the current study highlight the implications of sex-
dependent factors associated with BDNF expression and signaling. A review by Chan 
and Ye (2017) summarizes several of the sex-specific and sex-dependent actions of 
BDNF across animal and human models, including differences in levels of circulating 
BDNF in the CNS, sex-specific phenotypes associated with BDNF expression and 
signaling, and sex-dependent signaling mechanisms. The gonadal hormone estrogen has 
been shown to modulate BDNF expression through multiple pathways in hippocampal 
and other cortical neurons, while the less-studied testosterone has shown to positively 
regulate BDNF expression in motor neurons, the hippocampus, and animal brain 
homogenates (Chan & Ye, 2017). Additionally, gonadal hormones have been associated 
with the regulation of BDNF receptor TrkB (Chan & Ye, 2017). As gonadal hormones 
change throughout the lifespan, ultimately leading to reductions in late life, the 
supportive functions of these hormones on BDNF signaling may be reduced, leading to 
potential cascading effects in the development and progression of ADRD (Scharfman & 
MacLusky, 2006). The current research demonstrated sex-dependent effects for each of 
the BDNF SNPs selected (protein and receptor genes), thus adding indirect evidence that 
sex-specific factors are associated across both BDNF protein and receptor pathways.  
The current study has several strengths, including a large, population-based 
sample with longitudinal follow-up. This was especially important as the associations 
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between BDNF SNPs and cognitive decline were non-linear, with some SNPs 
demonstrating changes in direction after approximately five years of follow-up. 
Additionally, the study sample included persons with dementia in earlier stages of disease 
relative to other studies (mean baseline duration = 2.9 years). Thus, with extended 
follow-up (maximum of 13.28 years), we were able to follow persons with dementia 
across the course of severity. Also, most attrition was due to death of the participant, 
rather than artificial dropout. To our knowledge, no other research has included as large 
of a sample over as long of a study course. Furthermore, the use of linear-mixed effect 
modeling that does not exclude participants on a listwise basis demonstrated an 
advantage over previous research that employed more restricted methods. Finally, the 
sample being population-based is likely to be more broadly representative of community 
dwelling persons with dementia than other studies that rely on clinical samples. 
The current research includes some limitations. The CCSMA population 
characteristics include participants that are largely Caucasian, have relatively high levels 
of education, and broadly identify with a regional religious group, thereby limiting the 
generalizability of the results. Additionally, one of the SNPs in the current sample 
(rs56164415) did not reach HWE (Matyi et al., 2017). However, the genetic structure of 
the Utah population has been identified as having low inbreeding coefficients (O'Brien et 
al., 1994) and disequilibrium was not found across all other SNPs. While the current 
study included multiple dementia etiologies (68% AD with or without another dementia, 
14% VaD, and 18% other dementia), specific associations by underlying cause of 
dementia were not able to be investigated. However, while the accumulation of abnormal 
proteins specific to dementia etiology has been described (e.g. tauopathy in AD; alpha-
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synuclein in LBD), early disruptions in BDNF signaling have been a proposed shared 
mechanism across neurodegenerative syndromes (Benussi et al., 2017), though less is 
known about the role of BDNF across the progression of the disease. Finally, though the 
proposed exploratory nature of the current research found several associations, only three 
remained statistically significant after Bonferroni correction. However, prior to 
conservative statistical correction, each association was consistent regarding the direction 
of effects. Of note, while the current study generally did not show any domain-specific 
effects of cognitive progression by BDNF genotype, it largely supported the MMSE as an 
adequate measure to detect general cognitive changes over time in persons with 
dementia. This may highlight that the MMSE was more sensitive to detect changes over 
time (possibly due to a higher range of values compared to other measures used) and may 
also suggest that the cognitive effects of BDNF are more generally widespread in ADRD.  
 There are several avenues of future research, including continuing to broadly 
elucidate sex-dependent effects of dementia progression in ADRD (Mielke et al., 2014). 
Further investigation into BDNF genetics may show interactions with lifestyle strategies 
to determine potential strategies for intervention, and how these interventions may differ 
across sex. For example, both physical activity (Di Liegro et al., 2019) and dietary 
changes (Beilharz et al., 2015) have been associated with BDNF expression and signaling 
and reductions in cognitive decline in aging brains. Additionally, investigation of the 
interaction of BDNF genetics and sex across dementia subtype in adequately powered 
samples may highlight differences in disease progression.  
 In conclusion, the current study demonstrated that cognitive progression in 
ADRD was associated with sex-dependent effects of SNPs that code for BDNF or its 
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receptors. These results highlight the need for further investigation of both sex-dependent 















Alzheimer’s disease and related disorders (ADRD) are a major public health 
concern in the United States, with Alzheimer’s disease (AD) being the fifth leading cause 
of death in individuals aged 65 and older (Alzheimer's Association, 2018). In addition to 
the hallmark cognitive deficits associated with ADRD (e.g. memory impairment), 
neuropsychiatric symptoms (NPS) occur at high frequencies (Chung & Cummings, 2000; 
Lyketsos et al., 2011). NPS (also termed neurobehavioral symptoms) are a constellation 
of psychiatric symptoms (e.g. depression, agitation, anxiety, psychosis, etc.) associated 
with an underlying neuropathological disease (e.g. Alzheimer’s disease). While the 
course of NPS in ADRD is highly variable, the prevalence of NPS in ADRD is common, 
with an estimated 50% of individuals having at least one NPS during the course of 
dementia (Steinberg et al., 2008). In AD, apathy, depression, and agitation, are the most 
frequent NPS in early stages of the disease, while aggression, delusions, and 
hallucinations, are often seen in later stages (Lyketsos et al., 2011). NPS also persist in 
severe dementia, with 98% of one sample exhibiting at least one symptom (Rozum et al., 
2019). Euphoria or elation is relatively rare in AD [~1%; (Tschanz et al., 2011)], and the 
presence of such may warrant investigation of another dementia etiology, such as 
frontotemporal dementia (Lyketsos et al., 2011). 
 NPS are associated with dementia progression. As mild cognitive impairment 
(MCI) has been implicated in conversion to dementia, mild NPS (termed Mild Behavioral 
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Impairment) may also be a prodrome to dementia (Ismail et al., 2016). NPS also predict 
more rapid progression to severe AD and earlier death (Peters et al., 2015). The 
relationship between NPS and the cognitive symptoms of dementia suggests shared 
similar etiology or risk factors.  
 
Neurotrophins in NPS and ADRD 
 
 A large body of research has implicated neurotrophic factors in both the 
development and progression of psychiatric disorders, such as depression, anxiety, and 
schizophrenia (Autry & Monteggia, 2012; Kalia & Costa, 2015) and ADRD (Dawbarn & 
Allen, 2003). Broadly, neurotrophic factors such as brain-derived neurotrophic factor 
(BDNF) and nerve-growth factor (NGF) are widely distributed in the central nervous 
system and promote synaptic growth and survival and differentiation of neurons [see 
Dawbarn and Allen (2003) and Huang and Reichardt (2001) for a full review of 
neurotrophic factors and their signaling pathways]. Recent reviews have called for an 
investigation of the overlap of neurotrophic biomarkers of NPS in dementia (Wenzler et 
al., 2017; Zanardini et al., 2016).  
 
BDNF Single Nucleotide Polymorphisms and NPS in ADRD 
 Neurotrophic genetics have been implicated in both neuropsychiatric conditions 
in late life (e.g. depression) (Pei et al., 2012) and AD (Fukumoto et al., 2010; Ji et al., 
2015; Lin et al., 2014; Matyi et al., 2017). One of the most studied is the BDNF single 
nucleotide polymorphism (SNP) Val66Met (i.e. rs6265; G196A). Val66Met is considered 
a functional SNP with a valine to methionine substitution at codon 66 of the BDNF gene 
and has been shown to affect activity-dependent production of BDNF in the hippocampus 
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(Egan et al., 2003). Presence of the minor Met allele has been associated with an 
increased risk for AD, with sex-dependent effects demonstrating an increased risk for 
female carriers only (Fukumoto et al., 2010; Lin et al., 2014).  However, others have 
found no association with Val66Met and AD risk (Ji et al., 2015; Matyi et al., 2017).  
 The investigation of genetic associations between BDNF and NPS in ADRD is 
relatively new, with limited research conducted. One study demonstrated an increased 
risk for AD-related depression for the minor alleles of both BDNF Val66Met (OR = 1.80, 
95% CI = 1.19-2.72) and G11757C (OR = 1.90, 95% CI = 1.25-2.90) in 245 Italian 
individuals with AD (Borroni et al., 2009). Two other BDNF SNPs were also 
investigated (C270T and rs2949045) and were not associated with AD-related depression 
risk. Similar results have been reported in a Chinese sample of 336 patients with AD, 
showing an increased risk for AD-related depression in the minor alleles of both BDNF 
Val66Met (OR = 1.75, 95% CI = 1.27-2.41) and G11757C (OR = 1.69, 95% CI = 1.19-
2.38), with no association for BDNF C270T or G712A (Zhang et al., 2011). Another 
exploratory study investigated the association of BDNF SNPs Val66Met, C270T, and 
G712A on NPS in 248 individuals with AD, showing only an association with the minor 
allele of C270T and hallucinations (OR = 3.25, 95% CI = 1.22-8.62) (Zdanys et al., 
2009). In a Brazilian study which examined Val66Met and depression and anxiety in 104 
individuals with Parkinson’s disease, the authors found an increased risk in major allele 
homozygotes (G/G) for both depression (OR = 3.4, 95% CI = 1.02-11.39) and anxiety 
(OR = 4.0, 95% CI = 1.12-14.94) (Cagni et al., 2017). In a study examining sex-
dependent effects, Pivac et al. (2011) found that the minor Met allele of Val66Met was 
associated with psychotic symptoms (i.e. delusions and hallucinations) in men only, in a 
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Caucasian Croatian sample. One limitation across current studies is the reliance on 
hospital/clinic convenience samples of AD, thereby limiting the generalizability of the 
results. To the best of our knowledge, no exploration of the association between BDNF 
genetics and NPS has occurred in a community-based sample of ADRD. Additionally, 
the majority of studies have focused specifically on depression in AD. Furthermore, 
statistical analyses have predominantly been restricted to dominant model comparisons, 
likely due to small minor allele frequencies in some samples. This is a limitation as even 
the widely studied BDNF SNP Val66Met has not demonstrated a clear inheritance pattern 
for AD or NPS risk, and other inheritance patterns (e.g. codominant) warrant 
investigation. Lastly, previous research has demonstrated sex-dependent effects of BDNF 
SNPs for AD risk (Fukumoto et al., 2010; Lin et al., 2014; Matyi et al., 2017), though 
only one study has examined sex-dependent effects of BDNF SNPs in NPS in AD and 
was limited to investigation of only psychotic symptoms (Pivac et al., 2011). 
The current study utilized extant data from 931 individuals with ADRD from a 
large population-based study of risk factors of dementia and its progression, to examine 
the association between several BDNF SNPs and NPS after the onset of dementia. The 







The current research used extant data from 931 individuals identified with 
dementia from the Cache County Study on Memory in Aging [CCSMA; see Breitner et 
al. (1999)], with follow-up in the CCSMA or the ancillary Cache County Dementia 
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Progression Study [DPS; see Tschanz et al. (2011)]. The county-wide ascertainment of 
dementia in those aged 65 years or older in 1995, occurred in 4 triennial waves that 
occurred in 1995, 1998, 2002, and 2005 (Breitner et al., 1999; Miech et al., 2002). 
Demographic and genetic variables were ascertained, including age, level of education, 
and genotype at apolipoprotein E (APOE). The majority (99%) of participants were 
Caucasian. All procedures were approved by the Institutional Review Boards of Utah 






A multi-staged dementia screening and assessment protocol was performed at all 
four waves of the CCSMA. Cognitive screening was conducted using an adaptation 
(Tschanz et al., 2002) of the 100-point modified Mini-Mental State Examination (3MS) 
(Teng & Chui, 1987) or if unable, dementia screening with a proxy using the Informant 
Questionnaire for Cognitive decline (IQCODE) (Jorm & Jacomb, 1989). In Waves 1 and 
2, participants who scored < 87 on the 3MS or whose IQCode was above 3.27 were sent 
to the Dementia Questionnaire (DQ) stage, consisting of an interview with a 
knowledgeable informant regarding identification of dementia symptomology. 
Participants identified as “questionable dementia” or “probable dementia”, (rated by a 
neuropsychologist or geropsychiatrist) or who were members of a randomly selected 
panel to complete all stages of screening and assessment, were selected to complete a 
clinical assessment. The clinical assessment included neuropsychological testing, medical 
and neurological evaluation, and clinical interview with a knowledgeable informant. 
Results of the assessment were reviewed and preliminary diagnoses of a cognitive 
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condition (if any) were assigned. Diagnoses of dementia followed Diagnostic and 
Statistical Manual (DSM-III-R) criteria (APA, 1987). The expert panel reviewed all 
clinical data, diagnosed dementia, and assigned age of onset based on a chronology of 
symptoms when the individual met DSM-III-R criteria. Differential diagnosis of AD and 
vascular dementia (VaD) followed criteria specified by the National Institute of 
Neurological and Communicative Disorders and Stroke and the Alzheimer’s Disease and 
Related Disorders Association (NINCDS-ADRDA; McKhann et al., 1984) and National 
Institute of Neurological Disorders and Stroke and Association Internationale pour la 
Recherché et l’Enseignement en Neurosciences (NINDS-AIREN; Román et al., 1993), 
respectively. Persons who were not identified with dementia at a given wave were 
followed at the subsequent wave(s) using similar procedures, except for the elimination 
of the DQ stage in Waves 3 and 4 and completion of a clinical assessment for those aged 
90 and above. Those with prodromal AD or dementia received an 18-month clinical 
assessment. 
 
Dementia Progression Study 
 
In 2002, surviving individuals diagnosed with incident dementia in CCSMA in 
waves 1-4 were invited to enroll in a follow-up study of dementia progression (Tschanz 
et al., 2011). The follow-up visits were similar to those of the CCSMA clinical 




 The Neuropsychiatric Inventory (NPI) assesses NPS that are commonly seen in 
dementia, including delusions, hallucinations, dysphoria, anxiety, agitation/aggression, 
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euphoria, disinhibition, irritability/lability, apathy, and aberrant motor behavior 
(Cummings et al., 1994). The 10-item NPI was administered to a knowledgeable 
informant/caregiver by a trained research nurse in waves 1 and 2 and the 12-item version 
[included sleep and appetite disturbance; Cummings (1997)] in waves 3, 4 and the DPS. 
For consistency across waves, analyses will be restricted to the 10-items only. If a 
symptom was endorsed, the caregiver was asked to rate the frequency (1 = occasionally, 
less than once per week; 2 = often, about once per week; 3 = frequently, several times per 
week; 4 = very frequently, once or more per day or continuously) and severity (1 = mild; 
2 = moderate; 3 = severe) of each symptom domain. The frequency and severity ratings 
were multiplied to calculate a summary score for each domain (range 0 – 12) and then 
summed for a total NPI score (range 0 – 120). The NPI has shown both adequate content 
and concurrent validity [correlations with Behavioral Symptoms in Alzheimer’s Disease 
(BEHAVE-AD) and Hamilton Depression Rating Scale (HDRS) items range r = 0.33 – 
0.77; p < 0.05] and reliability [internal consistency: α = 0.88; between-rater: range 89.4 – 
100%; 3 week test-retest: range r = 0.51 – 0.97; Cummings et al. (1994)]. Exploratory 




APOE genotyping was completed on buccal DNA as described previously 
(Breitner et al., 1999). BDNF genotyping was performed for four BDNF-related SNPs 
[rs6265 (Val66Met;), rs56164415 (C270T), rs2289656 (receptor trkB), and rs2072446 
(receptor p75NTR)] using standard TaqMan® Assays (Life Technologies). Due to the 
unknown model of inheritance of these SNPs, codominant (A/A vs. A/a vs. a/a) models 
were assessed as sample sizes allowed, otherwise followed by dominant (A/A vs. A/a and 
53 
 
a/a) models. The Hardy-Weinberg Equilibrium was previously performed on the total 
CCSMA sample (Matyi et al., 2017) and showed all BDNF SNPs but one (rs56164415) 




 Factors associated with BDNF genetics and NPS in ADRD were examined in 
statistical models. These include age of dementia onset, sex, level of education, APOE 
genotype (no E4 allele vs. one or more E4 allele). Furthermore, as neurotrophic 
mechanisms have implications in all neurodegenerative disease, dementia type [AD with 





Descriptive statistics were performed for the sample, including comparisons for 
participants included vs. excluded in the analyses using Chi-square tests for categorical 
variables and independent samples t-tests for continuous variables. A series of linear 
mixed-effects models was used to investigate the association of BDNF SNP inheritance 
on individual and total NPI symptoms, including the covariates discussed above. Linear 
mixed-effects models for longitudinal data allow for missing data across time points and 
do not exclude cases on a list-wise basis (Oberg & Mahoney, 2007). As NPS presentation 
was hypothesized to include different starting points and different trajectories for each 
participant, both random intercepts and slopes were employed to account for this 
variance. Due to the non-normal nature of NPI scores (positively skewed), also found in 
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previous research of CCSMA, a natural log transformation was employed to reduce error 
from violations of data normality assumptions. 
Statistical models were constructed as follows: trajectory was assessed for each 
dependent NPI variable comparing intercept only, time, and quadratic time (i.e. time2). 
Thereafter, main effect models included all covariates of interest, run separately for each 
SNP. Covariates were retained regardless of statistical significance due to previous 
empirical support on their effects of NPS presentation in dementia. Interaction terms 
were subsequently included in each model, starting with investigation of the association 
of a SNP on NPS presentation over time (SNP x time and time2). Likelihood Ratio Tests 
(LLRT) were employed to determine improvement in model fit (p < .05) of nested 
models. Additional interactions were then built to include hypothesized effects of sex 
[SNP x time (or time2) x sex] and were compared to lower order models using LLRT. 
When minor allele frequencies allowed, model building started with codominant (A/A vs. 
A/a vs. a/a) comparisons, or otherwise employed dominant (A/A vs. A/a and a/a) models. 
Maximum likelihood estimation (ML) was used during the iterative building process, 
while restricted maximum likelihood estimation (REML) was used on final models to 
obtain parameter estimates for all factors. To account for possible multiple comparisons 
effects, Bonferroni correction was applied to the final models (4 SNPs x 10 outcomes = 













 Out of 931 eligible participants with dementia, 51 participants were excluded due 
to lack of genotyping data across all four BDNF/BDNF receptor SNPs, leaving a final 
sample of 880. This sample was composed of 61.3% women, with a mean age of 
dementia onset at 82.0 years (SD = 7.1), and a mean education level of 13.0 years (SD = 
3.0). Excluded participants had longer mean duration of dementia pre-baseline (p = .021) 
and lower mean level of education (p = .026) compared to included participants. Table 8 
summarizes descriptive statistics for included vs. excluded participants. 
 
Table 8            
            
Study II: Baseline Participant Characteristics Comparing those Included vs Excluded 
in Analyses 
 
Variable Included (n = 880) Excluded (n = 51)    
M SD n % M SD n % T χ2 p 
Onset Age 82.0 7.1   82.6 5.7   -0.40  .689 
Dem Dur (yrs) 2.9 2.7   3.8 3.1   2.30  .021* 
Education (yrs) 13.0 3.0   12.0 2.6   -2.22  .026* 
Sex          0.12 .730 
   Male   341 38.8   18 35.3    
   Female   539 61.3   33 64.7    
APOE E4 
 Allele 
         0.77 .379 
   No E4   455 51.7   28 54.9    
   1 or more E4   422 48.0   19 37.3    
   Missing   3 0.3   4 7.8    
Dementia Type          1.23 .541 
   AD a   600 68.2   34 66.7    
   VaD   119 13.5   5 9.8    
   Other   161 18.3   12 23.5    
Note. Dem Dur = Baseline Dementia Duration 
a AD with or without a second type of dementia 




The final sample was then stratified by sex to identify differences per 
hypothesized sex effects. Compared to men, women were older at dementia onset (p < 
.001), had fewer years of education (p < .001), and differed in dementia etiology, namely 
higher frequency of AD and lower frequency VaD only (p < .001). Additionally, there 
were no significant differences in genotype frequencies between men and women. 
Baseline Total NPI score was also examined and showed no differences between sexes. 
Table 9 shows the descriptive statistics by sex. 
 
Table 9            
            
Study II: Descriptive Comparisons by Sex 
 
Variable Female (n = 539) Male (n = 341)    
M SD n % M SD N % t χ2 P 
Onset Age 82.7 6.9   80.9 7.3   -3.84  <.001*** 
BL Dem Dur (yrs) 3.1 2.6   2.8 2.8   -1.66  .097 
Education (yrs) 12.6 2.6   13.5 3.5   4.00  <.001*** 
Follow-up (yrs) 1.9 2.4   1.9 2.3   0.36  .719 
APOE4 E4          0.97 .324 
   No E4   271 50.3   184 54.0    
   1 or more E4   266 49.4   156 45.7    
   Missing   2 0.4   1 0.3    
Dementia Type          16.89 <.001*** 
   AD a   395 73.3   205 60.1    
   VaD   63 11.7   56 16.4    
   Other   81 15   80 23.5    
Prev/Inc Dem          0.40 .525 
   Prevalent   204 37.8   121 35.5    
   Incident   335 62.2   220 64.5    
SNP            
   rs6265          0.08 .961 
      G/G   344 60.1   222 61.8    
      G/a   167 29.2   105 29.2    
      a/a   22 3.8   13 3.6    
      Missing   39 6.8   19 5.3    
   rs2289656          0.6 .742 
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      C/C   341 59.6   213 59.3    
      C/t   159 27.8   100 27.9    
      t/t   21 3.7   17 4.7    
      Missing   51 8.9   29 8.1    
   rs2072446          4.34 .114 
      C/C   475 83   319 88.9    
      C/t   48 8.4   18 5    
      t/t   4 0.7   2 0.6    
      Missing   45 7.9   20 5.6    
   rs56164415          0.06 .811 
      C/C   459 80.2   294 81.9    
      C/t   64 11.2   38 10.6    
      t/t   0 0   0 0    
      Missing   49 8.6   27 7.5    
BL NPI Total 5.8 9.5   5.2 9.8   -0.76  .448 
Note. BL Dem Dur = Baseline Dementia Duration; Prev/Inc Dem = Prevalent and 
Incident Dementia Cases; BL NPI Total = Baseline NPI Total Score 
a AD with or without a second type of dementia 
* p < .05. ** p < .01. *** p < .001. 
 
  Due to the markedly skewed nature of NPI outcome variables, a natural log 
transformation was applied to total NPI score and the cluster scores. Prior to the 
transformation, 1 point was added to each score as a natural log of 0 is undefined. All 
model figures demonstrate back transformation of log values to original NPI score 
values. Furthermore, NPI Elation was not investigated due to limited endorsement over 
the course of the study (<1%). Appendix Supplemental Figures A 2 and A 3 show the 
histogram of NPI Total before and after transformation. 
 
Overview of Exploratory Statistical Models by SNP 
 
In models that demonstrated increased NPS over time, the inclusion of a non-
linear (quadratic) time component to that of a linear term for time represented the best 
model fit (-2 LLRT p < .001). Dementia type demonstrated a consistent main effect such 
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that individuals within the Other Dementia category had higher Total NPI scores 
compared to AD (p < .05). Note that models testing interactions of dementia type with 
each SNP (or including interactions with sex) did not achieve convergence, likely due to 
limited sample size. Thus, dementia type was retained as a covariate in all statistical 
models if its inclusion improved model fit. Results of statistical models testing study 
hypotheses are presented by each SNP. 
 
Rs6265 (Val66Met; G196A) 
 
 Rs6265 (codominant inheritance pattern) demonstrated different rates of change 
on NPI Delusions and Agitation/Aggression [ANOVA statistics: F(1022, 2) = 7.66, p 
<.001 and F(785, 2) = 10.68, p <.001; respectively, for interaction between rs6265 x 
time2). Figure 12 demonstrates NPI Delusions over time by rs6265 genotype and shows 
that minor homozygotes (a/a) had a more rapid increase over the first several years 
compared to the major allele carriers (G/G and G/a), though this declined rapidly after 
approximately 5 years post baseline. For NPI Agitation/Aggression by rs6265, Figure 13 
demonstrates that within the first 5 years from baseline, minor allele carriers (a/a and 
G/a) had a more rapid increase compared to major homozygotes, though this effect was 
attenuated over time. Both NPI Delusions and Agitation/Aggression models remained 
significant at the Bonferroni adjusted p value. 
Participant sex did not show a significant interaction with rs6265 across all NPI 
domains. Additionally, rs6265 was not associated with the rate of change for NPI Total 
Score, Hallucinations, Depression, Anxiety, or Aberrant Motor Behavior. Models for NPI 
Apathy, Irritability, and Disinhibition did not converge. Table 10 shows the fully adjusted 





NPI Delusions Score Over Time by rs6265 Genotype 
 















NPI Agitation/Aggression Score Over Time by rs6265 Genotype 
 
Note. Shaded region is one standard error of the mean. 
 
Table 10 
               
Fully Adjusted rs6265 Models by NPI Outcome 
               



















































(0.002) .0026** - - 










































APOE E4               
   No E4 - - - - - - - - - - - - - - 
   1 or 

















              
   AD a - - - - - - - - - - - - - - 
































   Male - - - - - - - - - - - - - - 














   G/G - - - - - - - - - - - - - - 




























              
   G/G x 
   Time2 - - - - - - - - - - - - - - 
   G/a x 
   Time2 
- - 0.003 (0.005) .5413 - - 
-0.017 
(0.004) <.001*** - - - - - - 
   a/a x 
   Time2 - - 
-0.049 
(0.013) <.001*** - - 
-0.035 
(0.013) .0064** - - - - - - 
Note. All models included all covariates, as well as main effects and lower order 
interaction terms for each significant interaction, though only highest order interactions 
are reported for each outcome; BL Dem Dur = Baseline Dementia Duration; Total = NPI 
Total; Del = NPI Delusions; Hal = NPI Hallucinations; Agi/Agg = NPI 
Agitation/Aggression; Dep = NPI Depression; Anx = NPI Anxiety; AMB = NPI Aberrant 
Motor Behavior 
a AD with or without a second type of dementia 




Due to the absence of homozygous minor allele carriers in rs56164415, all models 
compared heterozygous carriers (C/t) to homozygous major allele carriers (C/C). 
Rs56164415 genotypes differed in rates of change on NPI Agitation/Aggression 
[ANOVA statistic: F(298, 1) = 15.81, p <.001 for the interaction between rs56164415 x 
time2]. Figure 14 demonstrates NPI Agitation/Aggression over time by rs56164415 
genotype and shows that minor allele carriers (C/t) increased more rapidly after 
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approximately 5 years post baseline compared to the major homozygotes (C/C). The NPI 
Agitation/Aggression model remained significant at the Bonferroni adjusted p value.  
The association between rs56164415 and change in NPI Apathy over time 
differed between male and female participants [ANOVA statistic: F(1693, 1) = 4.55, p = 
.0330 for the interaction between rs56164415 x sex x time2]. Figure 15 illustrates the sex 
difference, in that male minor allele carriers (C/t) appeared to have an initial decline in 
apathy compared to major homozygotes (C/C) over the first 2 years post baseline, but a 
more rapid increase thereafter. Female minor allele carriers (C/t) did not differ from 
major homozygotes (C/C) in course of apathy over the duration of observation. The NPI 
Apathy model did not remain significant at the Bonferroni adjusted p value. 
Rs56164415 was not associated with the rate of change in NPI Total Score, 
Delusions, Depression, Anxiety, Hallucinations, Irritability, Disinhibition, or Aberrant 















NPI Agitation/Aggression Score Over Time by rs56164415 Genotype  
 
Note. Shaded region is one standard error of the mean. Predicted values rise above scale 














NPI Apathy Score Over Time for Females and Males by rs56164415 Genotype 
 




Table 11                     
                     
Fully Adjusted rs56164415 Models by NPI Outcome 
                     



























































Time2 -0.024 (0.003) <.001*** 
-0.010 








(0.002) .0024** - - - - - - 

























































APOE E4                     
   No E4 - - - - - - - - - - - - - - - - - - - - 
   1 or more 






















 Type                     
   AD a - - - - - - - - - - - - - - - - - - - - 






































Sex                     
     Male - - - - - - - - - - - - - - - - - - - - 



















Rs56164415                     
   C/C - - - - - - - - - - - - - - - - - - - - 




















 x Time2                     
   C/C x 




   C/t x 
   Time2 - - - - - - 
0.019 
(0.005) <.001*** - - - - - - - - - - - - 
Rs56164415 
 x Sex x 
 Time2 
                    
   C/C x 
   Male 
   x Time2 
- - - - - - - - - - - - - - - - - - - - 
   C/t x 
   Female x 
   Time2 
- - - - - - - - - - -0.063 (0.029) .0330* - - - - - - - - 
Note. All models included all covariates, as well as main effects and lower order interaction terms for each significant interaction, 
though only highest order interactions are reported for each outcome; BL Dem Dur = Baseline Dementia Duration; Total = NPI Total; 
Del = NPI Delusions; Hal = NPI Hallucinations; Agi/Agg = NPI Agitation/Aggression; Dep = NPI Depression; Apa = NPI Apathy; 
Anx = NPI Anxiety; Dis = NPI Disinhibition; Irr = NPI Irritability; AMB = NPI Aberrant Motor Behavior 
a AD with or without a second type of dementia 
* p < .05. ** p < .01. *** p < .001. 
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Rs2289656 (Receptor TrkB) 
The association between rs2289656 (codominant inheritance pattern) and rate of 
change in NPI Anxiety differed between male and female participants [ANOVA statistic: 
F(788, 2) = 3.62, p = .0271 for the interaction between rs2289656 x sex x time2). Figure 
16 illustrates this sex association in that female minor homozygotes (t/t) had a more rapid 
increase over the first several years compared to the major allele carriers (C/C and C/t), 
though declined rapidly after approximately 5 years post baseline. Male minor 
homozygotes (t/t) appeared to have an initial decline followed by a rapid increase, though 
this did not reach statistical significance. The NPI Apathy model did not remain 
significant at the Bonferroni adjusted p value. 
Rs2289656 was not associated with the rate of change for NPI Total Score, 
Delusions, Hallucinations, Depression, Apathy, Disinhibition, Irritability, or Aberrant 
Motor Behavior. Models for NPI Agitation/Aggression did not converge. Table 12 shows 














NPI Anxiety Score Over Time for Females and Males by rs2289656 Genotype 
 




Table 12                   
                   
Fully Adjusted rs2289656 Models by NPI Outcome 
                   
Variable Total Del Hal Dep Apa Anx Dis Irr AMB 
 β (SE) p β (SE) p β (SE) p β (SE) p β (SE) p β (SE) p β (SE) p β (SE) p β (SE) p 














































(0.004) .7171 - - - - - - 






















































APOE E4                   
   No E4 - - - - - - - - - - - - - - - - - - 
   1 or more 




















 Type                   
   AD a - - - - - - - - - - - - - - - - - - 





































Sex                   
   Male - - - - - - - - - - - - - - - - - - 

















Rs2289656                   
   C/C - - - - - - - - - - - - - - - - - - 








































   C/C x 
   Male x 
   Time2 
- - - - - - - - - - - - - - - - - - 
   C/t x 
   Female x 
   Time2 
- - - - - - - - - - -0.000 (0.008) .9975 - - - - - - 
   t/t x 
   Female x 
   Time2 
- - - - - - - - - - -0.145 (0.054) .0073** - - - - - - 
Note. All models included all covariates, as well as main effects and lower order interaction terms for each significant interaction, 
though only highest order interactions are reported for each outcome; BL Dem Dur = Baseline Dementia Duration; Total = NPI Total; 
Del = NPI Delusions; Hal = NPI Hallucinations; Dep = NPI Depression; Apa = NPI Apathy; Anx = NPI Anxiety; Dis = NPI 
Disinhibition; Irr = NPI Irritability; AMB = NPI Aberrant Motor Behavior 
a AD with or without a second type of dementia 
* p < .05. ** p < .01. *** p < .001. 
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Rs2072446 (Receptor p75NTR) 
Due to the infrequency of minor homozygotes, only dominant models (C/C vs. C/t 
and t/t) were examined. Rs2072446 genotype was associated with different rates of 
increase in NPI Delusions [ANOVA statistic: F(659, 1) = 5.03, p = .025 for the 
interaction between rs2072446 x time2]. Figure 17 illustrates this association in that 
minor allele carriers (C/t & t/t) had a greater rate of increase in delusions over the first 
several years compared to the major homozygotes (C/C), though this pattern was 
reversed after approximately 5 years post baseline. The NPI Delusions model did not 
remain significant at the Bonferroni adjusted p value. 
Rs2072446 was not associated with the rate of change for NPI Total Score, 
Depression, Apathy, Anxiety, Hallucinations, Agitation/Aggression, Disinhibition, or 
Aberrant Motor Behavior. Models for NPI Irritability did not converge. Table 13 shows 















NPI Delusions Score Over Time by rs2072446 Genotype 
 




Table 13                   
                   
Fully Adjusted rs2072446 Models by NPI Outcome 
                   
Variable Total Del Hal Agi/Agg Dep Apa Anx Dis AMB 




















































Time2 -0.026 (0.003) <.001*** 
-0.009 






(0.002) <.001*** - - - - 






















































APOE E4                   
   No E4 - - - - - - - - - - - - - - - - - - 
   1 or more 




















Type                   
   AD a - - - - - - - - - - - - - - - - - - 





































Sex                   
   Male - - - - - - - - - - - - - - - - - - 

















Rs2072446                   
   C/C - - - - - - - - - - - - - - - - - - 


















 x Time2                   




   Time2 
   C/t & t/t 
   x Time2 - - 
-0.012 
(0.005) .0253* - - - - - - - - - - - - - - 
Note. All models included all covariates, as well as main effects and lower order interaction terms for each significant interaction, 
though only highest order interactions are reported for each outcome; BL Dem Dur = Baseline Dementia Duration; Total = NPI Total; 
Del = NPI Delusions; Hal = NPI Hallucinations; Agi/Agg = NPI Agitation/Aggression; Dep = NPI Depression; Apa = NPI Apathy; 
Anx = NPI Anxiety; Dis = NPI Disinhibition; AMB = NPI Aberrant Motor Behavior 
a AD with or without a second type of dementia 







 In the current sample of 880 participants with ADRD from a longitudinal, 
population-based study, differential effects were observed across four BDNF SNPs in the 
rate of NPS progression over the course of dementia. Additionally, SNPs rs56164415 and 
rs22896556 demonstrated sex-dependent effects. These results add to the paucity of 
literature investigating the role of genes coding for BDNF or its receptors in NPS change 
over time, including sex-dependent factors. 
 The current study demonstrated that the course of NPS over time depends on 
BDNF SNP genotypes. The functional BDNF protein SNP rs6265 (Val66Met) showed 
that minor homozygotes (a/a) had more rapid early increase in severity of delusions and 
agitation/aggression. However, this effect attenuated over time. A similar pattern was 
observed for rs56164415 (C270T) such that minor allele carriers (C/t) exhibited increased 
agitation/aggression over the study compared to major homozygotes (C/C). For the low-
affinity BDNF receptor p75NTR SNP rs2072446, minor allele carriers (C/t and t/t) 
exhibited initial increased delusions compared to major homozygotes (C/C), though the 
effect attenuated over time. The attenuated effects seen in NPS over time are potentially 
due to increased variance associated with limited sample size for minor homozygotes 
(baseline N = 35 for rs6265), reduced follow-up time for minor allele homozygotes 
(within rs6265, approximately 7 years for a/a homozygotes compared to approximately 
12 years for G/G homozygotes), or due to treatment effects associated with increased 
NPS. As an individual is experiencing increased NPS, they are likely to receive treatment 
to reduce problematic behaviors, such as pharmacotherapy. Additionally, the course of 




2000; Lyketsos et al., 2011), such that specific NPS may become more or less 
pronounced given disease progression and interaction with environmental factors.  
 To date, previous research related to the effects of BDNF SNPs and NPS in 
dementia has been limited. The minor alleles of both rs6265 and G11757C have been 
associated with AD-related depression (AD-D) in Italian (Borroni et al., 2009) and 
Chinese (Zhang et al., 2011) samples, while both studies showed no associated for C270T 
(as well as rs2949045 and G712A, respectively) and AD-D. This is in contrast to the 
current study, which found no associations of any BDNF SNP on NPI Depression in a 
largely Caucasian sample, possibly highlighting population-dependent effects seen in 
previous research regarding AD risk (Ji et al., 2015). In a US study of 341 AD patients 
(97% Caucasian), minor allele carriers of C270T had higher occurrence of hallucinations 
than major homozygotes, while no differences were found in rs6265 and G712A across 
any NPI domain (Zdanys et al., 2009). The current study did not show an association of 
any BDNF SNP and hallucinations. Divergence in study results may be due to sample 
characteristics, such that our participants were older at onset, with relatively shorter mean 
duration of dementia at baseline, had longer mean and total duration of follow-up, as well 
as the inclusion of multiple forms of dementia. Nevertheless, while prior research was not 
directly replicated in the current sample, the increases seen in NPS for minor allele 
carriers across BDNF SNPs is consistent with prior research showing a disruption in 
BDNF signaling for minor allele carriers of rs6265 (Egan et al., 2003), as well as research 
showing disruptions in BDNF signaling in both neuropsychiatric conditions and 




Sex-dependent effects were also observed in the current study. Male minor allele 
carriers (C/t) of rs56164415 showed initially slower increases in severity of that then 
increased rapidly over time compared to major homozygotes, though no association was 
observed within females. Additionally, for the high-affinity BDNF receptor TrkB SNP 
rs2289656, male and female minor homozygotes exhibited differential rates of change in 
anxiety. Female minor homozygotes demonstrated an early rapid increase in anxiety that 
attenuated over time, while males did not statistically differ across genotype. These sex-
dependent effects add to the near-absent literature regarding sex effects of BDNF 
genetics in NPS progression in dementia. Only one previous cross-sectional study was 
identified that demonstrated minor allele risk for psychotic symptoms in male 
participants only in a Croatian Caucasian sample of 211 individuals with AD (Pivac et 
al., 2011). The differential effects of BDNF SNPs on NPS progression between male and 
female participants may be further explained by the interactions of gonadal hormones and 
BDNF signaling. Estrogen has been shown to modulate BDNF expression through 
multiple pathways in hippocampal and other cortical neurons, while the less-studied 
testosterone has been shown to positively regulate BDNF expression in motor neurons, 
the hippocampus, and animal brain homogenates (Chan & Ye, 2017). Additionally, 
gonadal hormones have been associated with the regulation of BDNF receptor TrkB 
(Chan & Ye, 2017). As gonadal hormones change throughout the lifespan, ultimately 
leading to reductions in late life, the supportive functions of these hormones on BDNF 
signaling may be reduced, leading to potential cascading effects in the development and 
progression of ADRD (Scharfman & MacLusky, 2006). The current research 




BDNF protein and BDNF TrkB receptor, respectively), adding indirect evidence that sex-
specific factors are associated across both BDNF protein and receptor pathways.  
Specific associations by underlying cause of dementia were not able to be 
investigated in the current sample, though there has been some research that has indicated 
differential effects of BDNF SNPs on NPS across dementia etiology. In a Brazilian 
sample of 104 Parkinson’s disease patients, rs6265 major homozygotes showed increased 
risk for both anxiety and depression compared to minor allele carriers (Cagni et al., 
2017). This is in contrast to the aforementioned studies demonstrating increased 
depression risk for rs6265 minor allele carriers in AD (Borroni et al., 2009; Zhang et al., 
2011). Nevertheless, while the accumulation of abnormal proteins specific to dementia 
etiology has been described [e.g. tauopathy in AD; alpha-synuclein in Lewy-body 
dementia (LBD)], early disruptions in BDNF signaling have been a proposed shared 
mechanism across neurodegenerative syndromes (Benussi et al., 2017), though less is 
known about the effects of BDNF in later stages of disease progression.  
The current study has several strengths, including a large, population-based 
sample with longitudinal follow-up. This is especially relevant when examining 
heterogenous NPS over the course of dementia. Additionally, the study sample included 
persons with dementia in earlier stages of disease relative to other studies (mean baseline 
duration = 2.9 years). Thus, with extended follow-up (maximum of 13.28 years), we were 
able to follow persons with dementia across the course of disease severity. Also, most 
attrition was due to death of the participant, rather than artificial dropout. To our 
knowledge, no other research has included as large of a sample over as long of a study 




participants on a listwise basis demonstrated an advantage over previous research that 
employed more restricted methods. Finally, the sample being population-based is likely 
to be more broadly representative of community dwelling persons with dementia than 
other studies that rely on clinical samples. 
The current research includes some limitations. The CCSMA population 
characteristics include participants that are largely Caucasian, have relatively high levels 
of education, and identify with a regional religious group, thereby limiting the 
generalizability of the results. Additionally, one of the SNPs in the current sample 
(rs56164415) did not reach HWE. However, the genetic structure of the Utah population 
has been identified as having low inbreeding coefficients (O'Brien et al., 1994) and 
disequilibrium was not found across all other SNPs. Furthermore, though the proposed 
exploratory nature of the current research found several associations, only three remained 
statistically significant after conservative Bonferroni correction. Of note, the current 
study did not account for concurrent treatment of NPS, such as medication use. The 
association of medication use in dementia is complex and may alter observed NPS 
presentation (Rosenberg et al., 2012), potentially through interactions between 
psychotropic medications and BDNF as demonstrated with antipsychotics in an animal 
model (Pillai et al., 2006). 
 Future research may investigate the relationship of BDNF SNP genotypes and 
targeted treatments for NPS in ADRD. Non-pharmacological treatments have 
demonstrated variable efficacy toward reducing NPS across dementia severity (Kverno et 
al., 2009), which may possibly be related to differential expression of BDNF across SNP 




allele carriers of Val66Met for post-traumatic stress disorder symptomology (Pitts et al., 
2019) and similar research is needed to investigate this effect in ADRD, especially as 
non-pharmacological treatments are considered the first line of defense for NPS treatment 
due to potential adverse effects associated with pharmacological treatments (Rosenberg et 
al., 2012). However, pharmacological targets for BDNF to reduce ADRD phenotypes 
(e.g. lentiviral gene delivery) have shown promising results in animal models (Nagahara 
et al., 2013).  
 In conclusion, the current study demonstrated that the course of NPS in ADRD 
was associated with SNPs that code for BDNF or its receptors and included sex-
dependent effects. These results highlight the need for further investigation of the role of 
both BDNF and sex-dependent effects in neurodegenerative disease progression. Doing 








SUMMARY AND CONCLUSIONS 
 
 
 The role of brain-derived neurotrophic factor (BDNF) has been implicated as a 
potential precursor to development of Alzheimer’s disease and related disorders (ADRD) 
(Benussi et al., 2017). Disruptions in BDNF protein expression and signaling have been 
shown in early stages of several neurodegenerative disorders, including Alzheimer’s 
disease (AD), Lewy-body dementia (LBD), and frontotemporal dementia (FTD), and 
these disruptions have been linked to the excess accumulation of abnormal proteins, such 
as tauopathies in AD and alpha-synuclein in LBD (Benussi et al., 2017; Zanardini et al., 
2016). However, less is known about the associations of BDNF on the course of ADRD, 
including cognitive progression and neuropsychiatric symptom (NPS) presentation. 
Previous literature has demonstrated that single nucleotide polymorphisms (SNPs) on 
genes coding for BDNF are associated with differential protein expression and receptor 
functioning, such as rs6265 (Val66Met) (Egan et al., 2003). Therefore, rs6265 and other 
SNPs have been investigated regarding cognitive progression in time-limited, clinical AD 
samples, though results generally indicated no association (Boots et al., 2017; Chuu et al., 
2006; Forlenza et al., 2010; Lim et al., 2013; Zdanys et al., 2009). However, research has 
shown that BDNF expression and signaling has several sex-dependent effects (Chan & 
Ye, 2017), and sex-dependent effects of BDNF SNPs have been observed in ADRD risk 
(Fukumoto et al., 2010; Li et al., 2017; Lin et al., 2014; Matyi et al., 2017), as well as 
cognitive progression in AD (Li et al., 2017). NPS have also shown differential 




clinical samples (Borroni et al., 2009; Cagni et al., 2017; Pivac et al., 2011; Zdanys et al., 
2009; Zhang et al., 2011), and with documented sex-dependent effects (Pivac et al., 
2011). The major limitations of the previous research are the use of relatively small, 
clinically-based samples with limited follow-up, and with limited investigation of 
potential sex-dependent effects. This restricts the conclusions drawn about how BDNF 
genetics interact with cognitive progression and NPS presentation over the highly 
variable course of ADRD. 
 The current studies consisted of examining both cognitive progression and NPS 
presentation of ADRD in relation to four BDNF SNPs associated with protein and 
receptor functioning. 880 individuals with prevalent (37%) or incident (63%) ADRD 
(68% AD with or without other dementia, 14% VaD; and 18% other dementia) and 
BDNF genotyping from the longitudinal, population-based Cache County Study on 
Memory in Aging and subsequent Dementia Progression Study were sampled and 
followed for a maximum of 13.3 years (M = 1.9, SD = 2.4). The results demonstrated that 
the rate of cognitive progression and NPS presentation over time were dependent across 
all BDNF SNP genotypes. Additionally, the results highlighted that cognitive progression 
across BDNF SNPs was entirely dependent on sex, and sex-dependent effects were also 
seen in anxiety and apathy for rs2289656 and rs56164415, respectively. 
The current studies build upon previous literature that 1) BDNF SNPs are 
associated with ADRD cognitive progression and NPS presentation over time and 2) sex-
dependent effects are observed in these changes. This provides indirect evidence 
regarding the role of differential BDNF expression and signaling in ADRD and the 




linked to the development of ADRD (Benussi et al., 2017) and the current results suggest 
these effects continue over time based on SNP genetics. BDNF expression and signaling 
have also been associated with sex-specific factors, such as gonadal hormones. Research 
has shown that both androgens and estrogens are associated with BDNF functioning 
through several pathways (Chan & Ye, 2017). Sex differences in the association of 
BDNF genetics and the clinical expression of dementia may implicate such endogenous 
factors.  
A few practical implications arise from the growing understanding of BDNF 
genotypes on dementia progression, including individualized genetic counseling and 
available treatment to mitigate negative effects. Genetic counseling can provide an 
individual’s genetic profile to determine known relative risk and protective factors. The 
inclusion of BDNF genes within a dementia panel may be warranted as dementia 
etiologies are increasingly shown to be multifactorial and interactive. Additionally, as 
this research highlights the differential associations of BDNF SNPs on cognitive 
progression and NPS change over time, it is noteworthy to investigate potential therapies 
that target both cognitive stimulation and reduction of NPS. Physical activity is a 
promising avenue and has been associated with BDNF expression and signaling and 
reductions in cognitive decline (Di Liegro et al., 2019). Furthermore, results have shown 
that physical activity attenuates the effects of BDNF genetics on PTSD symptoms (Pitts 
et al., 2019) and investigation is warranted in ADRD samples. Diet is another possible 
avenue of intervention that can be implemented with relative ease in ADRD populations. 
Diets high in saturated fats and refined sugars have been associated with reduced BDNF 




increased BDNF functioning, and dietary factors have been linked with differential 
cognitive progression in older adults (Beilharz et al., 2015). Finally, while several issues 
remain in pharmacological treatment of both cognitive decline and NPS in ADRD, early 
treatment with BDNF therapies (e.g. lentiviral gene delivery) has shown promising 
results in reducing AD phenotypes in animal models (Nagahara et al., 2013).   
 In conclusion, the current research supports that cognitive decline and NPS 
changes over time in ADRD are associated with BDNF SNPs and include sex-dependent 
effects. Continued investigation into BDNF and other neurotrophin genetics may show 
interactions with lifestyle or environmental factors to determine potential targets for 
intervention. Furthermore, this research may show how these interventions may differ 
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Appendix Figure A 1. 
Baseline Bivariate Correlations of Cognitive Outcomes 
 
Note: Highlighted squares: p < .05 
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brain injury, neurodegenerative disease, and psychiatric disorders 
- Referral sources: primary care, neurology, Utah TBI Fund, Utah Office of 
Vocational Rehabilitation, area school districts, self-referred 
- Psychotherapy training in CBT, DBT, IPT modalities 
- Didactics in neurocognitive disorders, diversity training, and therapy modalities  
 
Utah State Student Health and Wellness, Logan UT (2017 – 2018) 
Supervisor: M. Scott DeBerard, Ph.D. 
- Interdisciplinary Primary Care 
- Service of approx. 10 therapy/behavioral health management clients weekly 
- Training in brief CBT, DBT therapy modalities; integrated behavioral health 
model 
- Didactics in health psychology, evaluation of liver transplant and spinal surgery 
candidates, and psychopharmacology 
 
Center for Persons with Disabilities: Clinical Services, Logan, UT (2016 – 2017) 
Supervisor: Martin Toohill, Ph.D. 




- Service of approx. 2 assessment clients per week 
- Lifespan patient population including neurodevelopmental and psychiatric 
disorders 
- Referral sources: primary care, area school districts, state disability services, self-
referred 
- Didactics in neurodevelopmental disorders and interdisciplinary practice 
 
Utah State University Psychology Community Clinic, Logan, UT (2016 – 2017) 
Supervisors: Susan Crowley, Ph.D. ABPP; Jenna Glover Ph.D. 
- Service of approx. 6 clients per week 
- Lifespan patient population of University and community-referred clients 
- Training in CBT, DBT, ACT, IPT, Schema therapy modalities  





Alzheimer’s Disease and Cognitive Disorders Lab (2014 – 2020) 
Utah State University, Logan, UT 
Supervisor/Principal Investigator: JoAnn Tschanz, Ph.D. 
- Epidemiological research investigating factors related to dementia and 
cognitive aging 
- Manuscript preparation and conference presentations, including posters/papers 
- Data analysis, cleaning, and organization 
- Peer mentoring and supervision of undergraduate students 
 
Academic Entitlement and Student/Instructor Communication (2014 – 2016) 
Utah State University, Logan, UT 
Principle Investigator: Louis Nadelson, Ph.D. 
- Designed online survey to examine academic entitlement, student/instructor 
communication attitudes, and self-reported behavior, including manuscript 
- Data analysis, cleaning, and organization 
 
Technology Adoption and Use of Everyday Technologies (TAUT) (2014 – 2015) 
Utah State University, Logan, UT 
Supervisor/Principal Investigator: JoAnn Tschanz, Ph.D. 
- Phone interviews, including brief assessment, for mid-study data collection 
- Data quality control and organization 
- Conference poster preparation 
 
Gray Matters (2014 – 2015) 
Utah State University, Logan, UT 
Principle Investigator: Maria Norton, Ph.D. 
- Data analysis, cleaning, and organization 





Utah Brain Lab (2012 – 2014) 
University of Utah, Salt Lake City, UT 
Supervisor/Principle Investigator: Matthew Euler, Ph.D. 
- Data analysis, cleaning, and organization 
- Conference poster preparation and presentation 
 
PEER-REVIEWED JOURNAL ARTICLES 
 
Burhanullah, M. H., Tschanz, J. T., Peters, M. E., Leoutsakos, J. M., Matyi, J., Lyketsos, 
C. G., & Rosenberg, P. B. (2020). Neuropsychiatric symptoms as risk factors for 
cognitive decline in clinically normal older adults: The Cache County Study. The 
American Journal of Geriatric Psychiatry. 28(1), 64-71. 
 
Matyi, J., Rattinger, G. B., Schwartz, S., Buhusi, M., & Tschanz, J. T. (2019). Lifetime 
estrogen exposure and cognition in late life: The Cache county study. Menopause. 
26(12), 1366-1374. 
 
Rozum, W. J., Cooley, B., Vernon, E., Matyi, J., & Tschanz, J. T. (2019). 
Neuropsychiatric symptoms in severe dementia: Associations with specific cognitive 
domains the Cache county dementia progression study. International Journal of Geriatric 
Psychiatry. 34(7). 
 
Vernon, E.K., Cooley, B., Rozum, W., Rattinger, G.B., Behrens, S., Mayti, J., Fauth, E., 
Lyketsos, C.G., & Tschanz, J.T. (2018). Caregiver-care recipient relationship closeness is 
associated with neuropsychiatric symptoms in dementia. American Journal of Geriatric 
Psychiatry. 27(4), 349-359. 
 
Behrens, S., Rattinger, G. B., Schwartz, S., Matyi, J., Sanders, C., DeBerard, M. S., 
Lyketsos, C. G., & Tschanz, J. T. (2018). Use of FDA approved medications for 
Alzheimer’s disease in mild dementia is associated with reduced informal costs of care. 
International Journal of Psychogeriatrics, 30(10), 1499-1507. 
 
Matyi, J. M., Tschanz, J. T., Rattinger, G. B., Sanders, C., Vernon, E. K., Corcoran, C. . . 
. & Buhusi, M. (2017). Sex differences in risk for Alzheimer’s disease related to 
neurotrophin gene polymorphisms: The Cache county memory study. Journal of 
Gerontology: Biological Sciences, 72(12), 1607-1613. 
 
Nadelson, L. S., Sias, C. M., Matyi, J., Morris, S. R., Cain, R., Cromwell, M., . . . & Xie, 
T. (2016). A world of information at their fingertips: College students’ motivations and 
practices in their self-determined information seeking. International Journal of Higher 




Matyi, J. & Tschanz, J. T. (2018). SSRIs. Encyclopedia of clinical neuropsychology (2nd 





Matyi, J. & Tschanz, J. T. (2018). Antidepressants. Encyclopedia of clinical 
neuropsychology (2nd ed.). J. S. Kreutzer, J. DeLuca, & B. Caplan (Eds). New York: 
Springer. 
 
Tschanz, J. T. & Matyi, J. (2018). Serotonin. Encyclopedia of clinical neuropsychology 
(2nd ed.). J. S. Kreutzer, J. DeLuca, & B. Caplan (Eds). New York: Springer. 
 
Tschanz, J. T., & Matyi, J. (2018). Senile dementia. Encyclopedia of clinical 
neuropsychology (2nd ed.). J. S. Kreutzer, J. DeLuca, & B. Caplan (Eds). New York: 
Springer. 
 
Sanders, C., Matyi, J., Tschanz, J. T., & Andersen, A. (2018). Alzheimer’s dementia. 
Encyclopedia of clinical neuropsychology (2nd ed.). J. S. Kreutzer, J. DeLuca, & B. 
Caplan (Eds). New York: Springer. 
 
PEER-REVIEWED CONFERENCE PRESENTATIONS 
 
Drewel, M., Gonzalez, H., Rattinger, G. B., Matyi, J., Hammond, A., Kauzor, K., 
Buhusi, M., & Tschanz, J. (2021). BDNF SNP C270T modifies the association between 
history of head injury and cognitive status in older adults. Gerontological Society of 
America, Phoenix, AZ, November 2021. 
 
Matyi, J., Rattinger, G. B., Schwartz, S., Buhusi, M., & Tschanz, J. T. Lifetime estrogen 
exposure is associate with cognitive status in late life: The Cache county study. 
Gerontological Society of America Annual Scientific Conference (Poster), Boston, MA, 
November 2018. 
 
Matyi, J., West, N., Rattinger, G. B., Vernon, E. K., Buhusi, M., & Tschanz, J. T. 
Reproductive window and moderating factors associated with risk for Alzheimer’s 
disease: The Cache county study. Alzheimer’s Association International Conference 
(Poster), Chicago, IL, July 2018. 
 
Behrens, S., Rattinger, G. B., DeBerard, M. S., Schwartz, S., Matyi, J., Sanders, C., & 
Tschanz, J. T. Antidementia medication use is associated with decreased informal costs 
in mild dementia. International Association of Gerontology and Geriatrics (Poster), San 
Francisco, CA, July 2017. 
 
Rozum, W., Cooley, B., Vernon, E., Richens, A., Matyi, J., & Tschanz, J. Specific 
cognitive/behavioral domains predict neuropsychiatric symptoms in severe dementia. 
The Rocky Mountain Psychological Association Annual Meeting (Poster), Salt Lake 
City, UT, April 2017. 
 
Sanders, C., Behrens, S., Tschanz, J., Matyi, J., Decker, M., Hovey, R., & Norton, M. 




matters study. The International Neuropsychological Society Annual Meeting (Poster), 
New Orleans, LA, February 2017. 
 
Vernon, E., Behrens, S., Matyi, J., & Tschanz, J. T. Sleep disturbances and its 
association with cognitive status in a population-based sample of older adults: The 
Cache country memory study. The International Neuropsychological Society Annual 
Meeting (Poster), New Orleans, LA, February 2017. 
 
Matyi, J., Rattinger, G., Sanders, C., Vernon, E. K., Corcoran, C., Kauwe, J. K., Buhusi, 
M., & Tschanz, J. Sex differences in neurotrophin genes and risk for Alzheimer’s disease. 
The Gerontological Society of America Annual Scientific Conference (Symposium 
Paper), New Orleans, LA, November 2016. 
 
Behrens, S., Sanders, C., Matyi, J., Tschanz J., Norton M., Hartin P., Cleland I., Scotney 
B., McClean S., Edwards, E., McIntyre, S., Wallace, C., Smith K., & Nugent C. Adoption 
of a smartphone reminding application and association with caregiver burden. The 
Gerontological Society of America Annual Scientific Conference (Poster), Orlando, FL, 
November 2015. 
 
Matyi, J. M., Kauwe, J., Sanders, C., Rattinger, G. B., Corcoran, C., Norton, M. C., 
Munger, R., Buhusi, M., & Tschanz, J. Neurotrophin single nucleotide polymorphisms 
and cognitive functioning in older adults: The Cache county study on memory in aging. 
Alzheimer’s Association International Conference (Poster), Washington, D.C., July 2015. 
 
Matyi, J. M., Behrens, S., Clark, C., Sanders, C., Chambers, S., Ferguson, M., Taylor, J., 
Kramer, A., Matangi, R., Papa, L., Fauth, E. B., Tschanz, J., & Norton, M. C. Dementia 
caregiving in a community-based sample of middle-aged adults is associated with lower 
episodic memory: The gray matters study. Alzheimer’s Association International 
Conference (Poster), Washington, D.C., July 2015. 
 
Rattinger, G. B., Matyi, J. M., Kauwe, J., Sanders, C., Corcoran, C., Norton, M., 
Munger, R., Buhusi, M., & Tschanz, J. Do medications that affect brain derived 
neurotrophic factor (BDNF) modify the associations between BDNF genotypes and 
cognitive functioning in older adults? The Cache county study. Alzheimer’s Association 
International Conference (Poster), Washington, D.C., July 2015. 
 
Niermeyer, M. A., Euler, M. J., Suchy, Y., Matyi, J., Schryver, H., Chon, D., Reddy, V. 
V., Gibbs, P., & Vaccariello, E. EEG correlates of individual differences in motor 
sequence planning and accuracy. Society for Neuroscience (Poster), Washington, D.C., 
November 2014. 
 
Matyi, J. M., Euler, M. J., Weisend, M. P., Jung, R. A., & Yeo, R. A. Intellectual ability 
predicts faster peak theta responses following repeat stimulus exposure. Utah Conference 
on Undergraduate Research (Poster), Provo, UT, February 2014. 
 





Matyi, J., & Schwebach, A. Management of traumatic brain injury in primary care. 




Course Instructor: PSY 3460 – Neuroscience I (Online) (2016 – 2017) 
Utah State University, Logan, UT 
Supervisor: JoAnn Tschanz, Ph.D. 
- Development of self-paced online course material 
- Grading and office hours 
 
Teaching Assistant: PSY 1010 – Introduction to Psychology (2016) 
Utah State University, Logan, UT 
Supervisor: Jennifer Grewe, Ph.D. 
- Grading, office hours, and lecturing   
 
Course Instructor: PSY 1010 – Introduction to Psychology (2015) 
Utah State University, Logan, UT 
Supervisor: Gretchen Peacock, Ph.D. 
- Development of course material 
- Lecturing, grading, and office hours  
 
Couse Instructor: PSY 1730 – Strategies for Academic Success (2014 – 2016) 
Utah State University, Logan, UT 
Supervisor: Dennis Kohler, M.S. 
- Development of course material 
- Lecturing, grading, and office hours  
 
Advisor: PSY 4950 – Undergraduate Apprenticeship (2014 – 2015) 
Utah State University, Logan, UT 
Supervisor: Jenn Grewe, Ph.D. 
- Supervised undergraduate researchers, 45 hours each on various projects   
 
PREVIOUS WORK EXPERIENCE 
 
Graduate Student Advisor: Academic Resource Center (2014 – 2015) 
Utah State University, Logan, UT 
Supervisor: Dennis Kohler, M.S. 
- Individual and group consultations for university students requiring academic 
support 
- Organization and delivery of monthly workshops on academic skills 
- Designed, implemented, and analyzed online survey for both site services use 
and course instruction enhancement  
 




West Valley City, UT 
Supervisor: Erica Kenney, M.S. 
- Worked with students at Title 1 school implementing behavior plans and 
progress monitoring 
- Collaboration with primary and special education teachers 
 
HONORS AND AWARDS 
 
USU Research and Graduate Studies Travel Award  (2015, 2016) 
USU Michael Bertoch Dementia Research Scholarship  (2016) 
USU Center for Women and Gender Travel Award  (2015) 
Alzheimer's Association International Conference, Travel Fellowship  (2015) 
Undergraduate Research Scholar at University of Utah  (2014) 
Dean’s List at University of Utah  (2012, 2013, 2014) 
UROP Assistantship at University of Utah  (2013) 
Departmental Honors Scholarship in Psychology at University of Utah  (2013) 
APA Academic Excellence in Psychology at Community Colleges  (2012) 




International Neuropsychological Society Student Affiliate  (2019 – Present) 
Psi Chi National Psychology Honor Society  (2012 – Present) 
Gerontological Society of America Student Member  (2016 – 2017) 
APA Division 40 (Clinical Neuropsychology) Student Affiliate  (2013 – 2014) 




Graduate Student Representative – USU Combined-Psychology Program  (2016 – 2017) 
USU Chapter Advisor – National Society of Collegiate Scholars  (2015 – 2016) 
Peer Manuscript Reviewer – Journal of International Psychogeriatrics  (2015) 
Volunteer Aide – Rolling Meadows Elementary  (2010 – 2014) 
 
 
 
